MOH | List of Subsidised Drugs

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Abacavir & Lamivudine	Tablet	Abacavir 600 mg + Lamivudine 300 mg	SDL
Abacavir, Dolutegravir & Lamivudine	Tablet	Abacavir 600 mg + Dolutegravir 50 mg + Lamivudine 300 mg	SDL
Abemaciclib	Tablet	50 mg, 100 mg, 150 mg	MAF	1) Abemaciclib in combination with an aromatase inhibitor as initial endocrine-based therapy for HR positive, HER2 negative, advanced or metastatic breast cancer. Pre/perimenopausal women treated with this combination could also receive a luteinizing hormone-releasing hormone agonist according to local clinical practice. 2) Abemaciclib in combination with fulvestrant for treating HR positive, HER2 negative, advanced or metastatic breast cancer in patients who have received prior endocrine therapy. Pre/perimenopausal women treated with this combination could also receive a luteinizing hormone-releasing hormone agonist according to local clinical practice. 3) Abemaciclib in combination with endocrine therapy for adjuvant treatment of patients with HR positive, HER2 negative, node-positive early breast cancer at high risk of recurrence. Maxiumum treatment duration: 2 years.
Abiraterone Acetate	Tablet	250 mg	SDL
Abrocitinib	Tablet	50 mg, 100 mg, 200 mg	MAF	Additional clinical criteria applies Treatment of moderate to severe atopic dermatitis (AD)
Absolute Alcohol	Injection	100%	SDL
Acalabrutinib	Capsule	100 mg	MAF	1) Monotherapy for previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients who are unsuitable for fludarabine-based therapy. 2) Monotherapy for chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients who have received at least one prior therapy. 3) Treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Acetazolamide	Tablet	250 mg	SDL
Acetic acid	Ear drops	2%, 3%, 4%, 5%	SDL
Acetylcysteine	Injection	5 g/25 mL	SDL
Acyclovir	Concentrate for infusion	250 mg/10 mL	SDL
Acyclovir	Infusion	250 mg	SDL
Acyclovir	Eye ointment	3%	SDL
Acyclovir	Tablet	200 mg, 400 mg, 800 mg	SDL
Acitretin	Capsule	10 mg, 25 mg	SDL
Adalimumab Biosimilar (Amgevita)	Prefilled autoinjector	40 mg/0.8 mL	SDL
Adalimumab Biosimilar (Amgevita)	Prefilled syringe	20 mg/0.4 mL, 40 mg/0.8 mL	SDL
Adefovir Dipivoxil	Tablet	10 mg	SDL
Adrenaline	Injection	1:1,000 (1 mg/mL), 1:10,000 (1 mg/10 mL)	SDL
Afatinib	Tablet	20 mg, 30 mg, 40 mg	MAF	Treatment of locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer
Albendazole	Oral suspension	400 mg/10 mL	SDL
Albendazole	Tablet	400 mg	SDL
Alectinib	Capsule	150 mg	MAF	Treatment of locally advanced or metastatic ALK mutation-positive non-small cell lung cancer
Alendronic Acid	Tablet	10 mg, 70 mg	SDL
Alendronic Acid & Colecalciferol	Tablet	Alendronic Acid 70 mg + Colecalciferol 2,800 international units, Alendronic Acid 70 mg + Colecalciferol 5,600 international units	MAF	1) For patients with osteoporosis (T-score ≤ -2.5) 2) For patients with osteopenia (T-score ≤ -1.5) and a history of non-trauma induced fracture
Alfacalcidol	Capsule	0.25 mcg, 1 mcg	SDL
Alfacalcidol	Oral drops	2 mcg/mL	SDL
Alfacalcidol	Tablet	0.25 mcg, 1 mcg	SDL
Alfuzosin Hydrochloride	Tablet	10 mg	SDL
Allopurinol	Tablet	100 mg, 300 mg	SDL
Alteplase	Infusion	50 mg/50 mL	SDL
Aluminium Hydroxide	Tablet	600 mg	SDL
Aluminium Hydroxide, Magnesium Trisilicate & Simeticone	Chewable tablet	Aluminium Hydroxide 250 mg + Magnesium Trisilicate 250 mg + Simeticone 30 mg	SDL
Aluminium Hydroxide, Magnesium Trisilicate & Simeticone	Oral suspension	Aluminium Hydroxide 400 mg/5 mL + Magnesium Trisilicate 400 mg/5 mL + Simeticone 30 mg/5 mL	SDL
Aluminium Oxide	Oral suspension	4%	SDL
Ambrisentan	Tablet	5 mg, 10 mg	MAF	Treatment of adults with a confirmed diagnosis of WHO Functional Class II or III pulmonary arterial hypertension (PAH) who have one of the following PAH aetiologies: • Idiopathic PAH • Heritable or familial PAH • PAH associated with connective tissue disease • Anorexigen-induced PAH • PAH associated with HIV infection
Amikacin	Injection	500 mg/2 mL	SDL
Amiloride & Hydrochlorothiazide	Tablet	Amiloride Hydrochloride 5 mg + Hydrochlorothiazide 50 mg	SDL
Amino Acids	Infusion	5%, 10%	SDL
Aminophylline	Injection	250 mg/10 mL	SDL
Amiodarone Hydrochloride	Injection	50 mg/mL	SDL
Amiodarone Hydrochloride	Tablet	200 mg	SDL
Amitriptyline	Tablet	10 mg, 25 mg	SDL
Amlodipine	Tablet	5 mg, 10 mg	SDL
Amoxicillin	Capsule	250 mg, 500 mg	SDL
Amoxicillin	Tablet	500 mg	SDL
Amoxicillin	Oral suspension	125 mg/5 mL, 250 mg/5 mL	SDL
Amoxicillin & Clavulanic Acid	Injection	Amoxicillin 500 mg + Clavulanic Acid 100 mg, Amoxicillin 1 g + Clavulanic Acid 200 mg	SDL
Amoxicillin & Clavulanic Acid	Oral suspension	Amoxicillin 200 mg/5 mL + Clavulanic Acid 28.5 mg/5 mL, Amoxicillin 600 mg/5 mL + Clavulanic Acid 42.9 mg/5 mL	SDL
Amoxicillin & Clavulanic Acid	Tablet	Amoxicillin 500 mg + Clavulanic Acid 125 mg, Amoxicillin 875 mg + Clavulanic Acid 125 mg	SDL
Amphotericin B	Injection	50 mg	SDL
Amphotericin B	Eye drops	1 mg/mL	SDL
Ampicillin	Injection	0.5 g	SDL
Anagrelide	Capsule	0.5 mg	MAF	Reduction of elevated platelet counts in patients with essential thrombocythaemia who are intolerant to their existing therapy or for whom other therapies are not considered appropriate
Anastrozole	Tablet	1 mg	SDL
Anidulafungin	Infusion	100 mg	SDL
Antazoline Hydrochloride & Tetryzoline Hydrochloride	Eye drops	Antazoline Hydrochloride 0.5 mg/mL + Tetryzoline Hydrochloride 0.4 mg/mL	SDL
Anti-Rabies Immunoglobulin	Injection	300 units/2 mL	SDL
Apixaban	Tablet	2.5 mg, 5 mg	SDL
Aprepitant	Capsule	80 mg	MAF	Prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
Aprepitant	Capsule	80 mg & 125 mg (Tripack)	SDL
Aqueous Cream	Cream	Emulsifying Ointment 30% with either Chlorocresol 0.1% or Phenoxyethanol 0.1%	SDL
Ascorbic Acid	Tablet	100 mg	SDL
Ascorbic Acid	Injection	1 g/20 mL, 500 mg/5 mL	SDL
Aspirin	Tablet	100 mg, 300 mg	SDL
Atazanavir	Capsule	200 mg, 300 mg	SDL
Atenolol	Tablet	50 mg, 100 mg	SDL
Atezolizumab (Tecentriq)	Concentrate for infusion	840 mg/14 mL, 1200 mg/20 mL	MAF	1) Atezolizumab in combination with bevacizumab biosimilar (subsidised brand) for treating advanced unresectable hepatocellular carcinoma in patients who have not received prior systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system. 2) Atezolizumab in combination with a platinum agent and etoposide, for untreated extensive-stage small-cell lung cancer. 3) For untreated metastatic non-small cell lung cancer (NSCLC), in patients whose tumours express PD-L1 with a tumour proportion score ≥50%, with no EGFR or ALK genomic tumour aberrations. 4) Treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for metastatic NSCLC. 5) Atezolizumab in combination with bevacizumab biosimilar (subsidised brand), and platinum-doublet chemotherapy, for the treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who had not received prior chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for metastatic NSCLC. 6) Atezolizumab in combination with platinum-doublet chemotherapy, for untreated metastatic non-squamous non-small cell lung cancer (NSCLC), in patients with no EGFR or ALK genomic tumour aberrations. 7) Adjuvant treatment following complete resection for patients with Stage II to IIIA non-small cell lung cancer (NSCLC) whose tumours have PD-L1 expression on ≥50% of tumour cells and whose disease has not progressed following platinum-based adjuvant chemotherapy. Maximum duration of treatment: 12 months.
Atorvastatin	Tablet	10 mg, 20 mg, 40 mg, 80 mg	SDL
Atracurium	Injection	25 mg/2.5 mL, 50 mg/5 mL	SDL
Atropine Sulfate	Eye drops	0.5%, 1%	SDL
Atropine Sulfate	Injection	0.6 mg/mL	SDL
Avelumab (Bavencio)	Concentrate for infusion	200 mg/10 mL	MAF	1) Maintenance treatment of locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-based chemotherapy. Avelumab may be given at a dose of 10 mg/kg up to a maximum of 800 mg, every 2 weeks. 2) Treatment of metastatic merkel cell carcinoma. Avelumab may be given at a dose of 10 mg/kg up to a maximum of 800 mg, every 2 weeks. 3) Avelumab in combination with axitinib for untreated advanced renal cell carcinoma. Avelumab may be given at a dose of 10 mg/kg up to a maximum of 800 mg, every 2 weeks.
Axitinib	Tablet	1 mg, 5 mg	MAF	1) For previously treated advanced renal cell carcinoma 2) Axitinib in combination with avelumab for untreated advanced renal cell carcinoma. Avelumab may be given at a dose of 10 mg/kg up to a maximum of 800 mg, every 2 weeks.
Azacitidine	Injection	100 mg	SDL
Azathioprine	Tablet	25 mg, 50 mg	SDL
Azithromycin	Extended-release oral suspension	2 g	SDL
Azithromycin	Injection	500 mg	SDL
Azithromycin	Oral suspension	200 mg/5 mL	SDL
Azithromycin	Tablet	250 mg	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Bacillus Calmette-Guerin	Solution for intravesical use	12.5 mg, 40 mg, 80 mg	SDL
Baricitinib	Tablet	2 mg, 4 mg	MAF	Additional clinical criteria applies Treatment of adult patients with rheumatoid arthritis
Beclomethasone	Inhalation aerosol	250 mcg/dose	SDL
Beclomethasone Dipropionate	Inhalation aerosol	50 mcg/dose	SDL
Bendamustine	Concentrate for infusion	25 mg, 100 mg	SDL
Benzalkonium Chloride & Cetrimide	Cream	Benzalkonium Chloride 0.01% + Cetrimide 0.2%	SDL
Benzathine Benzylpenicillin	Injection	2.4 million international units	SDL
Benztropine	Injection	2 mg/2 mL	SDL
Benztropine Mesilate	Tablet	2 mg	SDL
Benzhexol Hydrochloride	Tablet	2 mg	SDL
Benzoyl Peroxide	Gel	2.5%, 5%, 10%	SDL
Benzoyl Peroxide	Lotion	5%, 10%	SDL
Benzyl Benzoate	Topical emulsion	25%	SDL
Benzylpenicillin Sodium	Eye drops (preservative-free)	2,500 international units/mL	SDL
Benzylpenicillin Sodium	Injection	1 million international units, 5 million international units	SDL
Betaine	Powder	180 g	MAF	1) Treatment of classic homocysteinuria 2) Treatment of homocysteinuria secondary to sulfite oxidase deficiency, methionine synthase deficiency or cobalamin-related remethylation pathway defect
Betahistine Mesilate	Tablet	6 mg	SDL
Betamethasone (as Valerate)	Scalp lotion	0.1%	SDL
Betamethasone (as Valerate)	Cream	0.0125%, 0.025%, 0.05%, 0.1%	SDL
Betamethasone (as Valerate)	Ointment	0.025%, 0.05%, 0.1%	SDL
Betamethasone (as Valerate) & Clioquinol	Cream	Betamethasone 0.025% + Clioquinol 3%, Betamethasone 0.05% + Clioquinol 3%, Betamethasone 0.1% + Clioquinol 3%	SDL
Betamethasone Sodium Phosphate	Eye/ear drops	0.1%	SDL
Betamethasone Sodium Phosphate	Eye/ear drops	0.1%	SDL
Betaxolol	Eye drops	0.25%	SDL
Bethanechol Chloride	Tablet	10 mg	SDL
Bevacizumab	Intravitreal injection	25 mg/mL	MAF	1) Treatment of adults with visual impairment due to neovascular (wet) age-related macular degeneration 2) Treatment of adults with visual impairment due to macular oedema secondary to central or branch retinal vein occlusion 3) Treatment of adults with visual impairment due to diabetic macular oedema
Bevacizumab biosimilar (Mvasi)	Concentrate for infusion	100 mg, 400 mg	SDL
Bicalutamide	Tablet	50 mg	SDL
Bisacodyl	Enteric-coated tablet	5 mg	SDL
Bisacodyl	Rectal suppository	10 mg	SDL
Bismuth Subcitrate	Tablet	120 mg	SDL
Bismuth Subgallate	Rectal suppository	Bismuth Subgallate 200 mg + Zinc Oxide 120 mg	SDL
Bismuth Subsalicylate	Tablet	262.5 mg	SDL
Bisoprolol Fumarate	Tablet	2.5 mg, 5 mg	SDL
Bleomycin	Injection	15,000 international units (USP 15 units)	SDL
Blinatumomab (Blincyto)	Infusion	35 mcg	MAF	1) Treatment of B-precursor acute lymphoblastic leukaemia in first or subsequent complete remission with minimal residual disease (MRD) greater than or equal to 0.1% for: - up to a maximum of one cycle for induction in a lifetime; - and up to three additional cycles for consolidation in a lifetime in patients who are MRD negative. Complete remission is defined as a patient who: a) has 5% or less bone marrow blasts; and b) has no evidence of disease; and c) has a full recovery of peripheral blood counts with platelet count of more than 100,000 per microlitre; and d) has absolute neutrophil count of more than 1,000 per microlitre 2) Treatment of relapsed or refractory B-precursor acute lymphoblastic leukaemia for: - up to a maximum of two cycles for induction in a lifetime; and - up to three additional cycles for consolidation in a lifetime in patients who achieve a complete response after induction. Patients with Philadelphia chromosome positive disease must have previously received a tyrosine kinase inhibitor before receiving blinatumomab. Patients must not have received blinatumomab previously for the treatment of minimal residual disease (MRD)-positive B-ALL OR patients must have had a relapse-free period of at least six months following completion of treatment with blinatumomab for MRD. Complete response is defined as a patient who: - has 5% or less bone marrow blasts; and - has no evidence of disease; and - has platelet count of more than 50,000 per microlitre; and - has absolute neutrophil count of more than 500 per microlitre.
Boric Acid, Resorcinol & Phenol	Paint	Boric Acid 0.8% + Resorcinol 8% + Phenol 4%	SDL
Bortezomib	Injection	3.5 mg	SDL
Botulinum toxin type A complex (Botox)	Injection	50 units, 100 units	MAF	1) For adults with focal spasticity of the upper limbs due to stroke, who have Modified Ashworth Scale of 2 or more at the target muscle intended for botulinum toxin A treatment, and do not have the affected joint permanently fixed in position due to fibrotic shortening of the target muscle and are concurrently receiving physiotherapy 2) For adults with focal spasticity of the lower limbs due to stroke, who have Modified Ashworth Scale of 3 or more at the target muscle intended for botulinum toxin A treatment, and do not have the affected joint permanently fixed in position due to fibrotic shortening of the target muscle and are concurrently receiving physiotherapy 3) For adults with cervical dystonia, blepharospasm or hemifacial spasm 4) For children aged 2 years or older, with focal spasticity of the upper or lower limbs (including dynamic equinus foot deformity) due to cerebral palsy, and who do not have significant joint contractures (i.e. the affected joint is not permanently fixed in position due to shortening of the target muscle); and are concurrently receiving supportive therapy (e.g. physiotherapy or occupational therapy) 5) Prophylaxis of headaches in adults with chronic migraine who have had an inadequate response, intolerance, or contraindication to at least three migraine prophylactic medications.
Brentuximab vedotin (Adcetris)	Concentrate for infusion	50 mg	MAF	1) Brentuximab vedotin in combination with doxorubicin, vinblastine and dacarbazine (AVD), for treating patients with previously untreated CD30+ advanced classic Hodgkin lymphoma (cHL) who are intolerant or have contraindications to bleomycin. 2) Consolidation treatment of patients with CD30+ Hodgkin lymphoma (HL) who are at increased risk of relapse or progression following an autologous stem cell transplant (ASCT). Treatment should be stopped at 16 cycles, or earlier if disease progresses. 3) Treatment of patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): a) following autologous stem cell transplant (ASCT) or b) following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option. Treatment should be stopped at 16 cycles, or earlier if disease progresses. 4) Brentuximab in combination with cyclophosphamide, doxorubicin and prednisone (CHP), for untreated CD30+ peripheral T-cell lymphoma. 5) Treatment of patients with CD30+ cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy. Treatment should be stopped at 16 cycles, or earlier if disease progresses. 6) Treatment of relapsed or refractory systemic anaplastic large cell lymphoma. Treatment should be stopped at 16 cycles, or earlier if disease progresses.
Brigatinib	Tablet	30 mg, 90 mg, 180 mg	MAF	Treatment of locally advanced or metastatic ALK mutation-positive non-small-cell lung cancer.
Brimonidine Tartrate	Eye drops	0.15%	SDL
Brinzolamide	Eye drops	1%	SDL
Brinzolamide & Timolol	Eye drops	Brinzolamide 1% + Timolol 0.5%	SDL
Bromocriptine	Tablet	2.5 mg	SDL
Buclizine Hydrochloride	Tablet	25 mg	SDL
Budesonide	Inhalation powder	100 mcg/dose, 200 mcg/dose	SDL
Budesonide & Formoterol fumarate dihydrate (Symbicort Rapihaler)	Inhalation aerosol	Budesonide 80 mcg/dose + Formoterol fumarate dihydrate 2.25 mcg/dose (120 inhalations), Budesonide 160 mcg/dose + Formoterol fumarate dihydrate 4.5 mcg/dose (120 inhalations)	SDL
Budesonide & Formoterol fumarate dihydrate (Symbicort Turbuhaler)	Inhalation powder	Budesonide 160 mcg/dose + Formoterol fumarate dihydrate 4.5 mcg/dose (120 inhalations)	SDL
Budesonide & Formoterol fumarate dihydrate (Duoresp Spiromax)	Inhalation powder	Budesonide 160 mcg/dose + Formoterol fumarate dihydrate 4.5 mcg/dose (120 inhalations), Budesonide 320 mcg/dose + Formoterol fumarate dihydrate 9 mcg/dose (60 inhalations)	SDL
Bupivacaine Hydrochloride (hyperbaric)	Injection	0.5% (in dextrose 8%)	SDL
Bupivacaine Hydrochloride (isobaric)	Injection	0.5%	SDL
Buprenorphine	Sublingual tablet	0.2 mg	SDL
Busulfan	Injection	60 mg	SDL
Busulfan	Tablet	2 mg	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
C1 Esterase Inhibitor (Human)	Injection	500 international units/10 mL	MAF	Treatment of hereditary angioedema
Cabergoline	Tablet	0.5 mg	MAF	As a 2nd line agent for the management of hyperprolactinaemia in patients who have failed to respond or who are unable to tolerate bromocriptine
Cabozantinib	Tablet	20 mg, 40 mg, 60 mg	MAF	1) For previously treated advanced renal cell carcinoma 2) For untreated intermediate- or poor-risk advanced renal cell carcinoma 3) Treatment of advanced unresectable hepatocellular carcinoma in patients with disease progression after 1 or more prior lines of systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system
Calamine	Lotion	Calamine 15%	SDL
Calamine & Menthol	Lotion	Calamine 15% + Menthol 0.4%	SDL
Calcipotriol	Ointment	50 mcg/g	SDL
Calcipotriol	Scalp solution	50 mcg/mL	SDL
Calcipotriol & Betamethasone	Cutaneous foam	Calcipotriol 50 mcg/g + Betamethasone (as Diproprionate) 0.5 mg/g	SDL
Calcipotriol & Betamethasone	Gel	Calcipotriol 50 mcg/g + Betamethasone (as Diproprionate) 0.5 mg/g	SDL
Calcipotriol & Betamethasone	Ointment	Calcipotriol 50 mcg/g + Betamethasone (as Diproprionate) 0.5 mg/g	SDL
Calcitriol	Capsule	0.25 mcg, 0.5 mcg	SDL
Calcium	Syrup	20 mg to 23 mg Ca2+/mL	SDL
Calcium Acetate	Tablet	667 mg	SDL
Calcium Carbonate	Chewable tablet	1.25 g	SDL
Calcium Carbonate	Tablet	625 mg	SDL
Calcium Carbonate & Colecalciferol	Tablet	Calcium Carbonate 450 mg + Colecalciferol 5 mcg	SDL
Calcium Chloride Dihydrate	Injection	10%	SDL
Calcium Gluconate	Injection	10%	SDL
Calf Blood Extract (deproteinised)	Eye gel	8.3 mg/g	SDL
Calfactant	Intratracheal suspension	105 mg/3 mL, 210 mg/6 mL	SDL
Candesartan Cilexetil	Tablet	4 mg, 8 mg, 16 mg	MAF	Treatment of patients with heart failure who cannot tolerate angiotensin converting enzyme inhibitors
Capecitabine	Tablet	150 mg, 500 mg	SDL
Captopril	Tablet	12.5 mg, 25 mg	SDL
Carbamazepine	Controlled-release tablet	200 mg, 400 mg	SDL
Carbamazepine	Syrup	100 mg/5 mL	SDL
Carbamazepine	Tablet	200 mg	SDL
Carbimazole	Tablet	5 mg	SDL
Carboplatin	Injection	150 mg/15 mL, 450 mg/45 mL	SDL
Carmustine	Injection	100 mg	SDL
Carfilzomib	Infusion	30 mg	MAF	1) Carfilzomib in combination with lenalidomide or thalidomide or cyclophosphamide, plus dexamethasone, for patients with multiple myeloma who have received at least one prior therapy. Treatment with carfilzomib should be stopped after 18 cycles, or earlier if disease progresses. 2) Carfilzomib in combination with dexamethasone for patients with multiple myeloma who have received at least one prior therapy.
Carvedilol	Tablet	6.25 mg, 12.5 mg, 25 mg	SDL
Cefalexin	Capsule	250 mg	SDL
Cefalexin	Oral suspension	125 mg/5 mL	SDL
Cefazolin	Injection	1 g	SDL
Ceftazidime	Injection	1 g	SDL
Ceftriaxone	Injection	250 mg, 1 g, 2 g	SDL
Celecoxib	Capsule	200 mg	SDL
Ceritinib	Capsule	150 mg	SDL
Cetirizine	Solution	1 mg/mL	SDL
Cetirizine	Tablet	10 mg	SDL
Cetrimide	Topical solution	1%	SDL
Cetrimide	Shampoo	5%	SDL
Cetuximab (Erbitux)	Infusion	100 mg/20 mL	SDL
Charcoal (activated)	Capsule	200 mg	SDL
Charcoal (activated)	Granules	50 g	SDL
Charcoal (activated)	Oral suspension	50 g in sorbitol 96 g	SDL
Charcoal (activated)	Tablet	200 mg, 250 mg	SDL
Chloral Hydrate	Oral solution	200 mg/5 mL, 500 mg/5 mL	SDL
Chlorambucil	Tablet	2 mg	SDL
Chloramphenicol	Eye drops	0.5%	SDL
Chloramphenicol	Eye ointment	1%	SDL
Chlorhexidine Gluconate	Cream	1%	SDL
Chlorhexidine Salt	Mouthwash	0.2%	SDL
Chlorhexidine Salt	Topical solution	0.05%, 0.1%	SDL
Chlorhexidine Salt	Topical solution	4%	SDL
Chlorhexidine Salt	Mouthwash	0.2%	SDL
Chlorhexidine Salt & Alcohol	Topical solution	Chlorhexidine Salt 0.1% + Alcohol 70%, Chlorhexidine Salt 0.5% + Alcohol 70%	SDL
Chlorhexidine Salt & Cetrimide	Topical solution	Chlorhexidine Salt 0.015% + Cetrimide 0.15%	SDL
Chloroquine Phosphate	Tablet	150 mg	SDL
Chlorpheniramine	Syrup	4 mg/5 mL	SDL
Chlorpheniramine	Tablet	4 mg	SDL
Chlorpromazine	Injection	50 mg/2 mL	SDL
Chlorpromazine	Tablet	25 mg, 100 mg	SDL
Chlorpropamide	Tablet	250 mg	SDL
Chlortetracycline	Eye ointment	1%	SDL
Choline Salicylate & Cetylpyridinium Chloride	Oral gel	Choline Salicylate 8.7% + Cetylpyridinium Chloride 0.01%	SDL
Ciclosporin	Capsule	10 mg, 25 mg, 100 mg	SDL
Ciclosporin	Concentrate for infusion	50 mg/mL	SDL
Ciclosporin	Oral solution	100 mg/mL	SDL
Ciclosporin	Eye drop	0.1%	MAF	For the treatment of severe keratitis in dry eye disease in patients who fulfil the following criteria: • Have a corneal fluorescein staining (CFS) grade of 4 using the modified Oxford scale or equivalent; AND • Have an ocular surface disease index (OSDI) greater than or equal to 23; AND • Inadequate symptom control using optimised treatment with tear substitutes for at least 3 months
Cimetidine	Injection	200 mg/2 mL, 150 mg/mL	SDL
Cimetidine	Tablet	200 mg	SDL
Ciprofloxacin	Tablet	250 mg, 500 mg	SDL
Ciprofloxacin	Eye/ear drops	0.3%	SDL
Ciprofloxacin	Infusion	2 mg/mL	SDL
Cisplatin	Concentrate for infusion	50 mg/50 mL, 100 mg/100 mL	SDL
Citric Acid Monohydrate & Potassium Citrate	Oral solution	Citric Acid Monohydrate 0.25 g/5 mL + Potassium Citrate 1.5 g/5 mL	SDL
Clarithromycin	Modified-release tablet	500 mg	SDL
Clarithromycin	Tablet	250 mg, 500 mg	SDL
Clarithromycin	Injection	500 mg	SDL
Clarithromycin	Oral suspension	125 mg/5 mL	SDL
Clidinium & Chlordiazepoxide	Tablet	Clidinium Bromide 2.5 mg + Chlordiazepoxide 5 mg	SDL
Clindamycin	Capsule	150 mg	SDL
Clindamycin	Injection	150 mg/mL	SDL
Clobetasol propionate	Cream	0.05%	SDL
Clobetasol propionate	Ointment	0.05%	SDL
Clomiphene	Tablet	50 mg	SDL
Clomipramine	Tablet	25 mg	SDL
Clonazepam	Tablet	0.5 mg, 2 mg	SDL
Clopidogrel	Tablet	75 mg	SDL
Clotrimazole	Cream	1%	SDL
Clotrimazole	Lotion	1%	SDL
Clotrimazole	Powder	1%	SDL
Clotrimazole	Vaginal tablet	100 mg	SDL
Cloxacillin	Capsule	250 mg, 500 mg	SDL
Cloxacillin	Injection	250 mg, 500 mg	SDL
Cloxacillin	Syrup	125 mg/5 mL	SDL
Clozapine	Tablet	25 mg, 100 mg	SDL
Coal Tar	Cream	5%, 10%, 15%	SDL
Coal Tar	Lotion	20%	SDL
Coal Tar	Shampoo	25%	SDL
Coal Tar & Salicylic Acid	Ointment	Coal Tar 5% + Salicylic acid 2%	SDL
Cocaine	Solution	10%	SDL
Cocois Compound	Ointment	Coal Tar Solution 10% + Camphor 2% + Sulphur 4% + Salicylic Acid 2%	SDL
Codeine & Promethazine	Syrup	Codeine Phosphate 18 mg/10 mL + Promethazine 7.2 mg/10 mL	SDL
Codeine Phosphate	Tablet	30 mg	SDL
Coenzyme Q10	Capsule	50 mg	MAF	Treatment of mitochondrial disorders
Colchicine	Tablet	500 mcg	SDL
Colecalciferol	Tablet	1,000 units	SDL
Colestyramine	Powder for oral suspension	4 g	SDL
Compound Diphenhydramine	Syrup	Ranging from 5 mg/5 mL to 14 mg/5 mL	SDL
Compound Polyethylene Glycol (Fortrans)	Oral powder	-	SDL
Compound Sodium Lactate	Infusion	-	SDL
Conjugated Oestrogens	Tablet	0.3 mg, 0.625 mg	SDL
Conjugated Oestrogens	Vaginal cream	0.625 mg/g	SDL
Cyanocobalamin	Injection	1 mg/mL	SDL
Cyclophosphamide	Infusion	200 mg, 1 g	SDL
Cyclophosphamide	Tablet	50 mg	SDL
Cyproheptadine	Tablet	4 mg	SDL
Cyproterone Acetate	Tablet	50 mg	SDL
Cytarabine	Injection	1 g/10 mL	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Dabrafenib	Capsule	50 mg, 75 mg	MAF	1) To use with trametinib for treating locally advanced or metastatic anaplastic thyroid cancer in patients with a BRAF V600 mutation and with no satisfactory locoregional treatment options. 2) To use with trametinib for the treatment of advanced unresectable or metastatic malignant melanoma in patients with a BRAF V600 mutation. Patients must not have received prior treatment with a BRAF/MEK inhibitor for unresectable or metastatic melanoma. 3) To use with trametinib for the treatment of advanced non-small-cell lung cancer (NSCLC) in patients with a BRAF V600 mutation.
Dacarbazine	Injection	200 mg	SDL
Dacomitinib	Tablet	15 mg, 30 mg, 45 mg	SDL
Dactinomycin	Infusion	500 mcg	SDL
Dantrolene Sodium	Capsule	25 mg, 100 mg	SDL
Dapagliflozin	Tablet	5 mg, 10 mg	MAF	1) Treatment of type 2 diabetes mellitus, as a dual therapy • In combination with metformin for patients with HbA1c > 7% despite treatment with metformin monotherapy; • In combination with a sulfonylurea for patients with HbA1c > 7% despite treatment with sulfonylurea monotherapy and when metformin is contraindicated or not tolerated; 2) Treatment of type 2 diabetes mellitus as a triple therapy • In combination with metformin and a sulfonylurea for patients with HbA1c > 7% despite treatment with optimal doses of dual therapy 3) Treatment of type 2 diabetes mellitus in combination with insulin, with or without metformin 4) Treatment of adults with chronic heart failure (NYHA class II to IV) with reduced ejection fraction (left ventricular ejection fraction of 40% or less) as part of a quadruple therapy including a beta blocker, either an angiotensin-converting enzyme (ACE) inhibitor, angiotensin II receptor blocker (ARB) or angiotensin receptor-neprilysin inhibitor (ARNI), and a mineralocorticoid receptor antagonist (MRA) unless contraindicated or not tolerated. 5) Treatment of adults with chronic kidney disease: • who are receiving optimal standard treatment which includes an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) at maximum tolerated doses, unless contraindicated; and • have an estimated glomerular filtration rate (eGFR) of 25 to 75 mL/min/1.73m2 at the start of treatment; and • have type 2 diabetes mellitus or have a urinary albumin to creatinine ratio (uACR) of ≥ 200 mg/g (22.6 mg/mmol).
Dapsone	Tablet	100 mg	SDL
Darbepoetin alfa (NESP)	Injection	20 mcg/0.5 mL, 40 mcg/0.5 mL and 120 mcg/0.5 mL	SDL
Darunavir	Tablet	600 mg, 800 mg	SDL
Dasatinib	Tablet	20 mg, 50 mg, 70 mg	MAF	1) Treatment of newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukaemia in combination with chemotherapy. 2) Treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase. 3) Treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance or intolerance to prior treatment with imatinib. 4) Treatment of adults with treatment-resistant or treatment-intolerant chronic myeloid leukemia (CML) in chronic phase, accelerated phase, or myeloid or lymphoid blast phase or children with treatment-resistant or treatment-intolerant CML in chronic phase.
Daunorubicin	Injection	20 mg	SDL
Deferasirox	Tablet	90 mg, 360 mg	SDL
Deferiprone	Oral solution	100 mg/mL	SDL
Deferiprone	Tablet	500 mg	SDL
Deferoxamine Mesilate	Injection	500 mg	SDL
Degarelix	Powder and solvent for solution for injection	80 mg, 120 mg	MAF	Treatment of patients with advanced hormone-dependent prostate cancer
Denatured alcohol	Topical solution	70%	SDL
Denosumab (Prolia)	Prefilled syringe	60 mg/mL	MAF	1) Treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for non-metastatic breast cancer. 2) Treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer. 3) Treatment of patients with osteoporosis (T-score ≤ -2.5) at high risk for fracture.
Denosumab (Xgeva)	Injection	120 mg/1.7 mL	MAF	1) Prevention of skeletal-related events in patients with bone metastases from breast cancer, castration-resistant prostate cancer, lung cancer, and all other solid tumours. 2) Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
Dequalinium Chloride	Lozenge	0.25 mg	SDL
Desmopressin Acetate	Nasal drops	0.1 mg/mL	SDL
Desmopressin Acetate	Nasal spray	10 mcg/dose	SDL
Desmopressin Acetate	Tablet	0.1 mg, 0.2 mg	SDL
Dexamethasone	Tablet	500 mcg, 4 mg	SDL
Dexamethasone Phosphate	Injection	4 mg/mL	SDL
Dexmedetomidine	Concentrate for infusion	200 mcg/2 mL	SDL
Dextromethorphan Hydrobromide	Syrup	15 mg/5 mL	SDL
Dextromethorphan Hydrobromide	Tablet	15 mg	SDL
Dextrose & Potassium Chloride	Infusion	Dextrose 5% + Potassium Chloride 0.15%	SDL
Dextrose & Sodium Chloride	Infusion	Dextrose 2.5% + Sodium Chloride 0.45%, Dextrose 5% + Sodium Chloride 0.2%, Dextrose 5% + Sodium Chloride 0.45%, Dextrose 5% + Sodium Chloride 0.9%	SDL
Dextrose Monohydrate	Infusion	5%, 10%, 20%, 50%	SDL
Dextrose Monohydrate	Injection	50%	SDL
Dextrose, Potassium Chloride & Sodium Chloride	Infusion	Dextrose 5% + Potassium Chloride 0.15% + Sodium Chloride 0.33%, Dextrose 5% + Potassium Chloride 0.22% + Sodium Chloride 0.45%, Dextrose 5% + Potassium Chloride 0.30% + Sodium Chloride 0.45%, Dextrose 5% + Potassium Chloride 0.15% + Sodium Chloride 0.45%, Dextrose 5% + Potassium Chloride 0.15% + Sodium Chloride 0.9%	SDL
Diazepam	Enema	5 mg/2.5 mL	SDL
Diazepam	Injection	5 mg/mL	SDL
Diazepam	Tablet	2 mg, 5 mg, 10 mg	SDL
Dibasic Sodium Phosphate & Monobasic Sodium Phosphate	Enema	Dibasic Sodium Phosphate 7 g/118 mL + Monobasic Sodium Phosphate 19 g/118 mL, Dibasic Sodium Phosphate 3.5 g/59 mL + Monobasic Sodium Phosphate 9.5 g/59 mL	SDL
Diclofenac Sodium	Enteric-coated tablet	25 mg, 50 mg	SDL
Diclofenac Sodium	Injection	25 mg/mL	SDL
Diclofenac Sodium	Rectal suppository	12.5 mg, 25 mg, 50 mg	SDL
Diclofenac Sodium	Gel	1%	SDL
Diethylcarbamazine Citrate	Tablet	50 mg	SDL
Digoxin	Injection	100 mcg/mL, 250 mcg/mL	SDL
Digoxin	Oral solution	50 mcg/mL	SDL
Digoxin	Tablet	62.5 mcg, 250 mcg	SDL
Digoxin-specific Antibody Fragments	Injection	40 mg	SDL
Diltiazem Hydrochloride	Injection	10 mg, 50 mg	SDL
Diltiazem Hydrochloride	Sustained-release capsule	90 mg, 100 mg, 200 mg	SDL
Diltiazem Hydrochloride	Tablet	30 mg, 60 mg	SDL
Dimercaprol	Injection	50 mg/mL	SDL
Diosmin & Hesperidin	Tablet	Diosmin 450 mg + Hesperidin 50 mg	SDL
Diphenoxylate & Atropine Sulfate	Tablet	Diphenoxylate Hydrochloride 2.5 mg + Atropine Sulfate 25 mcg	SDL
Diphtheria & Tetanus Vaccine	Injection	Diphtheria Toxoid Vaccine minimum 2 international units/0.5 mL + Tetanus Toxoid Vaccine minimum 20 international units/0.5 mL	SDL
Diphtheria Antitoxin	Injection	10,000 units	SDL
Dipyridamole	Tablet	25 mg, 75 mg	SDL
Disodium Edetate	Eye drops	0.38%, 3%	SDL
Dobutamine	Concentrate for infusion	250 mg/5 mL, 250 mg/20 mL	SDL
Docetaxel	Infusion	20 mg, 80 mg, 160 mg	SDL
Dolutegravir	Tablet	50 mg	SDL
Dolutegravir & Lamivudine	Tablet	Dolutegravir 50 mg + Lamivudine 300 mg	SDL
Donepezil Hydrochloride	Oral disintegrating tablet	5 mg, 10 mg	MAF	For patients with mild to moderately severe Alzheimer's Disease who have swallowing difficulties and are unable to receive a film-coated tablet
Donepezil Hydrochloride	Tablet	5 mg, 10 mg	SDL
Dopamine Hydrochloride	Concentrate for infusion	200 mg/5 mL	SDL
Dothiepin Hydrochloride	Capsule	25 mg	SDL
Doxorubicin Hydrochloride	Injection	10 mg, 50 mg	SDL
Doxorubicin Hydrochloride (pegylated liposome)	Concentrate for infusion	20 mg/10 mL	SDL
Doxycycline	Capsule	100 mg	SDL
Droperidol	Injection	2.5 mg/mL	SDL
Dulaglutide	Prefilled pen	0.75 mg, 1.5 mg	MAF	For the treatment of type 2 diabetes mellitus 1) As a triple therapy in combination with two oral anti-diabetic drug (OAD) therapies for patients with inadequate glycaemic control despite treatment with optimal doses of dual OAD therapy, or as a dual therapy in combination with one OAD therapy if a dual OAD therapy is contraindicated or not tolerated; and 2) In combination with insulin and metformin, unless metformin is contraindicated or not tolerated
Durvalumab (Infimzi)	Concentrate for infusion	120 mg/2.4 mL, 500 mg/10 mL	MAF	1) Consolidation treatment of patients with locally advanced, unresectable NSCLC whose disease has not progressed following platinum-based chemo-radiation therapy. Treatment should be continued until disease progression or unacceptable toxicity or for a maximum of 12 months. Durvalumab retreatment is allowed at time of progression for up to 1 additional year if the initial treatment was stopped for reasons other than disease progression. 2) Durvalumab in combination with a platinum agent and etoposide, for untreated extensive-stage small-cell lung cancer.
Dutasteride	Capsule	0.5 mg	SDL
Dydrogesterone	Tablet	10 mg	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Efavirenz	Tablet	200 mg, 600 mg	SDL
Eltrombopag	Tablet	25 mg, 50 mg	MAF	1) Treatment of immune thrombocytopenia lasting six months or longer from diagnosis in patients who are intolerant or refractory to other treatments (e.g. corticosteroids, immunosuppressants). 2) Treatment of severe aplastic anaemia in patients who are refractory to immunosuppressive therapy (comprising horse anti-thymocyte globulin plus ciclosporin for at least 3 months) and have marrow cellularity <25% (or 25 to 50% with <30% residual haematopoietic cells), with at least 2 of the following: • neutrophils <0.5 x 10⁹/l • platelets <20 x 10⁹/l • reticulocyte count <20 x 10⁹/l (<60 x 10⁹/l for automated reticulocyte counting)
Empagliflozin	Tablet	10 mg, 25 mg	SDL
Emtricitabine & Tenofovir Disoproxil Fumarate	Tablet	Emtricitabine 200 mg + tenofovir disoproxil fumarate 300 mg	MAF	In combination with other antiretroviral agents for the treatment of HIV-1 infection
Emulsifying Ointment	Ointment	-	SDL
Enalapril Maleate	Tablet	5 mg, 10 mg, 20 mg	SDL
Enoxaparin Sodium (Clexane)	Injection	20 mg/0.2 mL, 40 mg/0.4 mL, 60 mg/0.6 mL, 80 mg/0.8 mL	SDL
Entacapone	Tablet	200 mg	SDL
Entecavir	Tablet	0.5 mg	SDL
Entecavir	Tablet	1 mg	MAF	Treatment of nucleos(t)ide-naïve patients with HBeAg-positive and HBeAg-negative chronic hepatitis B infection and evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease
Enzalutamide	Capsule	40 mg	MAF	1) In combination with androgen deprivation therapy (ADT) for treating patients with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC). 2) In combination with androgen deprivation therapy (ADT) for treating patients with metastatic hormone sensitive prostate cancer (mHSPC). 3) In combination with androgen deprivation therapy (ADT) for treating patients with metastatic castration-resistant prostate cancer (mCRPC).
Ephedrine Sulfate	Injection	30 mg/mL	SDL
Epirubicin	Injection	50 mg/25 mL	SDL
Epoetin Alfa (Eprex)	Prefilled syringe	2,000 international units/0.5 mL, 4,000 international units/0.4 mL, 10,000 international units/mL, 40,000 international units/mL	SDL
Epoetin Beta (Recormon)	Prefilled syringe	2,000 international units/0.3 mL, 4,000 international units/0.3 mL, 10,000 international units/0.6 mL, 30,000 international units/0.6 mL	SDL
Epoprostenol (Veletri)	Infusion	1.5 mg	MAF	Treatment of pulmonary arterial hypertension (idiopathic or heritable PAH or PAH associated with connective tissue diseases) in patients with WHO Functional Class III-IV symptoms
Eptifibatide	Injection	20 mg/10 mL	SDL
Eptifibatide	Infusion	75 mg/100 mL	SDL
Ergometrine Maleate	Injection	500 mcg/mL	SDL
Ergotamine & Caffeine	Tablet	Caffeine 100 mg + Ergotamine Tartrate 1 mg	SDL
Eribulin mesylate	Injection	1 mg/2 mL	MAF	1) Treatment of locally advanced or metastatic breast cancer in patients whose disease has progressed after at least two chemotherapy regimens for advanced disease. 2) Treatment of patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease.
Erlotinib	Tablet	100 mg, 150 mg	SDL
Erythromycin (as Ethyl Succinate)	Tablet	400 mg	SDL
Erythromycin (as Ethyl Succinate)	Oral suspension	200 mg/5 mL	SDL
Erythromycin (as Lactobionate)	Infusion	500 mg, 1 g	SDL
Erythromycin Stearate	Enteric-coated tablet	250 mg	SDL
Estradiol	Vaginal tablet	10 mcg	SDL
Etanercept (Enbrel)	Prefilled syringe	25 mg/0.5 mL, 50 mg/mL	MAF	Additional clinical criteria applies 1) Treatment of adult patients with non-radiographic axial spondyloarthritis 2) Treatment of juvenile idiopathic arthritis 3) Treatment of adult patients with chronic plaque psoriasis
Etanercept (Enbrel)	Injection	25 mg/mL	MAF	Additional clinical criteria applies 1) Treatment of adult patients with non-radiographic axial spondyloarthritis 2) Treatment of juvenile idiopathic arthritis 3) Treatment of adult patients with chronic plaque psoriasis
Ethambutol Hydrochloride	Tablet	100 mg, 400 mg	SDL
Ethanol	Solution	Minimum 95%	SDL
Ethionamide	Tablet	250 mg	SDL
Ethyl Chloride	Topical spray	88 g/100 mL	SDL
Etoposide	Capsule	50 mg	SDL
Etoposide	Concentrate for infusion	100 mg/5 mL	SDL
Etoricoxib	Tablet	60 mg, 90 mg, 120 mg	SDL
Etravirine	Tablet	200 mg	SDL
Everolimus	Tablet	0.25 mg, 0.75 mg	SDL
Everolimus	Tablet	2.5 mg, 5 mg, 10 mg	MAF	1) Treatment of unresectable or metastatic, well-differentiated, non-functional neuroendocrine tumours of gastrointestinal or lung origin and with progressive disease. 2) Treatment of unresectable, locally advanced or metastatic neuroendocrine tumours of pancreatic origin and with progressive disease.
Evolocumab (Repatha)	Solution for injection in prefilled autoinjector	140 mg/mL	MAF	Additional clinical criteria applies 1) Treatment of patients with non-familial hypercholesterolemia or mixed dyslipidaemia, with atherosclerotic cardiovascular disease and additional risk factors and LDL-c level above 1.8 mmol/L despite maximal tolerated lipid-lowering therapy for at least 12 weeks. Subsidy only applies when evolocumab is dosed at 140 mg every 2 weeks. 2) Treatment of patients with heterozygous familial hypercholesterolemia, with atherosclerotic cardiovascular disease and LDL-c level above 1.8 mmol/L despite maximal tolerated lipid-lowering therapy for at least 12 weeks. Subsidy only applies when evolocumab is dosed at 140 mg every 2 weeks. 3) Treatment of patients with heterozygous familial hypercholesterolemia, without atherosclerotic cardiovascular disease, and LDL-c level above 2.6 mmol/L despite maximal tolerated lipid-lowering therapy for at least 12 weeks. Subsidy only applies when evolocumab is dosed at 140 mg every 2 weeks. 4) Treatment of patients with homozygous familial hypercholesterolemia with LDL-c level above 1.8 mmol/L despite maximal tolerated statin-lowering therapy for at least 12 weeks.
Exemestane	Tablet	25 mg	SDL
Extended half-life recombinant factor VIII (Rurioctocog alfa pegol) (Adynovate)	Injection	250 international units, 500 international units, 1000 international units, 1500 international units, 2000 international units, 3000 international units	SDL
Ezetimibe	Tablet	10 mg	SDL

Active Ingredient(s)

Dosage Form

Strength(s)

Subsidy Class

Clinical Indication (where applicable)

Factor Eight Inhibitor Bypassing Activity (FEIBA)

Injection

500 units

SDL

Famotidine

Tablet

20 mg

SDL

Faricimab (Vabysmo)

Solution for injection

6 mg/ 0.05 mL

MAF

1) Treatment of adults with visual impairment due to neovascular (wet) age-related macular degeneration.
2) Treatment of adults with visual impairment due to diabetic macular oedema.

Fedratinib

Capsule

100 mg

MAF

For the treatment of splenomegaly and/or disease related symptoms in patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocytopenia myelofibrosis, including patients who have been previously exposed to ruxolitinib.

Fenofibrate

Capsule

100 mg, 300 mg

SDL

Fentanyl

Injection

50 mcg/mL

SDL

Fentanyl

Transdermal patch

12 mcg/hr, 25 mcg/hr, 50 mcg/hr

SDL

Ferric Carboxymaltose

Injection

500 mg/10 mL

SDL

Ferrous Fumarate

Tablet

200 mg

SDL

Ferrous Gluconate, Multivitamins & Minerals

Capsule

Ferrous Gluconate 250 mg + Vit B12 7.5 mcg + Vit C 50 mg + Folic Acid 1 mg + Sorbitol 25 mg + Copper Sulfate 200 mcg + Manganese Sulfate 200 mcg

SDL

Ferrous Sulphate & Vitamin B1 & Riboflavin & Nicotinamide

Tablet

Ferrous Sulphate 200 mg + Vitamin B1 3 mg + Riboflavin 1.5 mg + Nicotinamide 10 mg

SDL

Fexofenadine

Oral suspension

6 mg/mL

MAF

1. For relief of symptoms associated with seasonal allergic rhinitis in adults and children 2 years of age or older.
2. Treatment of uncomplicated skin
manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older.

Filgrastim

Injection

30 million units/0.5 mL (300 mcg/0.5 mL), 30 million units/mL (300 mcg/mL)

SDL

Finasteride

Tablet

5 mg

SDL

Fingolimod

Capsule

0.25 mg, 0.5 mg

MAF

Treatment of adults and children with relapsing-remitting multiple sclerosis.

Flecainide Acetate

Tablet

100 mg

SDL

Fluconazole

Capsule

50 mg, 100 mg, 150 mg

SDL

Fluconazole

Infusion

100 mg/50 mL

SDL

Fludarabine Phosphate

Injection

50 mg

SDL

Fludrocortisone Acetate

Tablet

0.1 mg

SDL

Flumazenil

Injection

0.1 mg/mL

SDL

Fluocinolone Acetonide

Cream

0.003125%, 0.00625%, 0.0125%, 0.025%

SDL

Fluorescein Sodium

Injection

10%

SDL

Fluorescein Sodium

Single-use eye drops

2%

SDL

Fluorouracil

Injection

500 mg/10 mL, 1 g/20 mL, 5 g/100 mL

SDL

Fluoxetine

Capsule

10 mg, 20 mg

SDL

Flupenthixol Decanoate

Injection

20 mg/mL, 40 mg/2 mL

SDL

Fluphenazine Decanoate

Injection

25 mg/mL

SDL

Fluticasone Furoate + Vilanterol (Relvar Ellipta)

Inhalation powder

Fluticasone Furoate 100 mcg/dose + Vilanterol 25 mcg/dose, Fluticasone Furoate 200 mcg/dose + Vilanterol 25 mcg/dose (30 inhalations)

SDL

Fluticasone Propionate

Inhalation aerosol

50 mcg/dose, 125 mcg/dose, 250 mcg/dose

SDL

Fluticasone Propionate + Salmeterol (Seretide Evohaler)

Inhalation aerosol

Fluticasone Propionate 50 mcg/dose + Salmeterol 25 mcg/dose (120 inhalations), Fluticasone Propionate 125 mcg/dose + Salmeterol 25 mcg/dose (120 inhalations), Fluticasone Propionate 250 mcg/dose + Salmeterol 25 mcg/dose (120 inhalations)

SDL

Fluticasone Propionate + Salmeterol (Seretide Accuhaler)

Inhalation Powder

Fluticasone Propionate 100 mcg/dose + Salmeterol 50 mcg/dose (60 inhalations), Fluticasone Propionate 250 mcg/dose + Salmeterol 50 mcg/dose (60 inhalations), Fluticasone Propionate 500 mcg/dose + Salmeterol 50 mcg/dose (60 inhalations)

SDL

Fluvoxamine Maleate

Tablet

50 mg

SDL

Folic Acid

Tablet

400 mcg, 5 mg

SDL

Folinic Acid

Injection

10 mg/mL

SDL

Fulvestrant

Injection

250 mg/5 mL

SDL

Furosemide

Injection

10 mg/mL

SDL

Furosemide

Tablet

40 mg

SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Gabapentin	Capsule	100 mg, 300 mg, 400 mg	SDL
Ganciclovir	Infusion	500 mg	SDL
Gefitinib	Tablet	250 mg	SDL
Gelatin Succinylated & Sodium Chloride	Infusion	Gelatin Succinylated 4 g/100 mL + Sodium Chloride 0.701 g/100 mL	SDL
Gemcitabine	Infusion	200 mg, 1000 mg, 2000 mg	SDL
Gemfibrozil	Capsule	300 mg	SDL
Gemtuzumab ozogamicin (Mylotarg)	Concentrate for infusion	5 mg	MAF	In combination with daunorubicin and cytarabine for patients with previously untreated de novo CD33-positive acute myeloid leukaemia (AML), if they: • do not have acute promyelocytic leukaemia, • only start induction therapy while waiting for cytogenetic test results or after confirming favourable, intermediate or unknown (due to inconclusive test results) cytogenetic risk, and • start consolidation therapy after confirming favourable, intermediate, or unknown cytogenetic risk.
Gentamicin	Injection	40 mg/mL	SDL
Gentamicin	Eye drops	0.3%	SDL
Gentian Violet	Paint	0.5%	SDL
Gilteritinib fumarate	Tablet	40 mg	MAF	Treatment of FLT-3 mutation positive relapsed / refractory acute myeloid leukaemia (AML). Gilteritinib is not recommended as maintenance therapy for patients after HSCT.
Glecaprevir & Pibrentasvir	Tablet	Glecaprevir 100 mg + pibrentasvir 40 mg tablet	MAF	Treatment of chronic hepatitis C (all genotypes) infection in treatment-naïve, pegylated interferon plus ribavirin (with or without sofosbuvir)-experienced and sofosbuvir plus ribavirin-experienced adults. Glecaprevir/Pibrentasvir should be used in line with the recommended treatment regimen and duration: Treatment-naive • 8 weeks’ treatment of glecaprevir/pibrentasvir for patients with hepatitis C virus (all genotypes) without cirrhosis or compensated cirrhosis (Child-Pugh A); Treatment-experienced • 8 weeks’ treatment of glecaprevir/pibrentasvir for patients with hepatitis C virus (genotypes 1,2,4,5,6) without cirrhosis • 12 weeks’ treatment of glecaprevir/pibrentasvir for patients with hepatitis C virus (genotypes 1,2,4,5,6) with compensated cirrhosis (Child-Pugh A) • 16 weeks’ treatment of glecaprevir/pibrentasvir for patients with hepatitis C virus (genotype 3) without cirrhosis or with compensated cirrhosis (Child-Pugh A)
Glibenclamide	Tablet	5 mg	SDL
Gliclazide	Tablet	80 mg	SDL
Glipizide	Tablet	5 mg	SDL
Glucagon	Injection	1 mg	SDL
Glycerol	Rectal suppository	1 g, 1.5 g, 2 g	SDL
Glycerol, Methyl Salicylate, Sodium Salicylate & Thymol Compound	Mouthwash	Glycerol 10% + Methyl Salicylate 0.03% + Sodium Salicylate 0.52% + Thymol 0.05%	SDL
Glyceryl Trinitrate	Oral spray	0.4 mg/dose	SDL
Glyceryl Trinitrate	Patch	5 mg, 10 mg	SDL
Glyceryl Trinitrate	Sublingual tablet	0.5 mg	SDL
Glycine	Irrigation solution	1.5%	SDL
Golimumab (Simponi)	Prefilled syringe	50 mg/0.5 mL, 100 mg/mL	MAF	Additional clinical criteria applies 1) Treatment of adult patients with rheumatoid arthritis 2) Treatment of adult patients with ankylosing spondylitis 3) Treatment of adult patients with psoriatic arthritis 4) Treatment of adult patients with non-radiographic axial spondyloarthritis 5) Treatment of adult patients with ulcerative colitis
Goserelin	Depot injection	3.6 mg, 10.8 mg	MAF	Treatment of locally advanced or metastatic prostate cancer.
Granisetron	Tablet	1 mg	SDL
Granisetron	Infusion	1 mg/mL, 3 mg/3 mL	SDL
Griseofulvin	Tablet	125 mg, 500 mg	SDL
Guaifenesin	Syrup	100 mg/5 mL	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Haemodialysis Concentrate 35X (Acetate Salt)	Solution	The diluted solution contains: Na⁺ 140.0 mmol/L, K⁺ 2.60 mmol/L, Ca²⁺ 1.38 mmol/L, Mg²⁺ 0.62 mmol/L, Cl^- 102 mmol/L, HCO^3- 45 mmol/L	SDL
Haemodialysis Concentrate 35X (Bicarbonate)	Solution (comprised 2 separate 10 L canisters: acidic & basic)	Acidic concentrate: KCl 5.5 g/L, NaCl 161.0 g/L, CaCl₂.2H2O 9.7 g/L, MgCl₂.6H2O 3.7 g/L, CH₃COOH (glacial) 8.8 g/L; Basic concentrate: NaCl 30.5 g/L, HCO^3- 66.0 g/L; Final diluted solution contains: Na⁺ 140 mmol/L, K⁺ 2.0 mmol/L, Ca²⁺ 1.8 mmol/L, Mg²⁺ 0.5 mmol/L, Cl^- 107.2 mmol/L, CH₃COO^- 4.0 mmol/L, HCO^3- 35.0 mmol/L	SDL
Haloperidol	Injection	5 mg/mL	SDL
Haloperidol	Oral solution	2 mg/mL	SDL
Haloperidol	Tablet	0.5 mg, 1.5 mg, 5 mg	SDL
Heparin Sodium	Injection	1,000 units/mL, 5,000 units/mL, 25,000 units/5 mL	SDL
Heparinised Saline	Injection (in sodium chloride 0.9%, preservative-free)	50 international units/5 mL	SDL
Hepatitis B Immunoglobulin	Injection	≥ 200 international units/mL (adults), ≥100 international units/mL (children)	SDL
Homatropine Hydrobromide	Eye drops	2%	SDL
Human Hemin	Infusion	250 mg/10 mL	MAF	Treatment of acute attacks of hepatic porphyria (acute intermittent porphyria, porphyria variegata, hereditary coproporphyria)
Human plasma coagulation factor XIII (pd-FXIII)	Injection	250 IU	MAF	Routine prophylaxis or treatment of bleeding episodes and peri-operative management of surgical bleeding in patients with congenital factor XIII deficiency.
Hydralazine Hydrochloride	Tablet	10 mg, 25 mg, 50 mg	SDL
Hydralazine Hydrochloride	Injection	20 mg/mL	SDL
Hydrochlorothiazide	Tablet	25 mg	SDL
Hydrocolloid (carboxymethylcellulose-containing)	Dressing	-	SDL
Hydrocolloid (carboxymethylcellulose-containing)	Gel	-	SDL
Hydrocortisone	Cream	0.5%, 1%	SDL
Hydrocortisone	Ointment	1%	SDL
Hydrocortisone	Tablet	10 mg	SDL
Hydrocortisone (as Sodium Succinate)	Injection	100 mg	SDL
Hydrocortisone Acetate	Rectal foam	10%	SDL
Hydrocortisone Acetate & Clioquinol	Cream	Hydrocortisone Acetate 1% + Clioquinol 3%	SDL
Hydrogen Peroxide	Mouthwash	3%	SDL
Hydrogen Peroxide	Topical solution	3%	SDL
Hydroxocobalamin	Injection	1 mg/mL	MAF	Treatment of cobalamin-related remethylation pathway defect causing cobalamin C deficiency
Hydroxychloroquine Sulphate	Tablet	200 mg	SDL
Hydroxychloroquine Sulphate	Tablet	200 mg	SDL
Hydroxyprogesterone Caproate	Injection	250 mg/mL	SDL
Hydroxyurea	Capsule	500 mg	SDL
Hydroxyzine Hydrochloride	Tablet	10 mg, 25 mg	SDL
Hydroxyzine Hydrochloride	Syrup	10 mg/5 mL	SDL
Hydroxyzine Hydrochloride	Capsule	10 mg, 25 mg	SDL
Hyoscine Butylbromide	Injection	20 mg/mL	SDL
Hyoscine Butylbromide	Tablet	10 mg	SDL
Hyoscine Hydrobromide Trihydrate	Injection	400 mcg/mL	SDL
Hypromellose	Eye drops	0.3%	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Ibuprofen	Oral liquid	100 mg/5 mL	SDL
Ibuprofen	Tablet	200 mg	SDL
Ifosfamide	Infusion	1 g	SDL
Imatinib	Capsule	100 mg, 400 mg	SDL
Imatinib	Tablet	100 mg, 400 mg	SDL
Imipenem & Cilastatin	Infusion	Imipenem 500 mg + Cilastatin 500 mg	SDL
Imipramine Hydrochloride	Tablet	10 mg, 25 mg	SDL
Indapamide	Tablet	2.5 mg	SDL
Indometacin	Capsule	25 mg	SDL
Inotuzumab ozogamicin (Besponsa)	Infusion	1 mg	MAF	Treatment of patients with relapsed or refractory CD22 positive B-precursor acute lymphoblastic leukemia (ALL) for: - up to a maximum of three cycles for induction in a lifetime, and - up to three additional cycles for consolidation in a lifetime in patients who achieve a complete response after induction. Patients with Philadelphia chromosome positive disease must have previously received a tyrosine kinase inhibitor before receiving inotuzumab. Complete response is defined as a patient who: a) has 5% or less bone marrow blasts; and b) has no evidence of disease; and c) has platelet count of more than 50,000 per microlitre; and d) has absolute neutrophil count of more than 500 per microlitre.
Infliximab Biosimilar (Ixifi)	Infusion	100 mg	SDL
Infliximab Biosimilar (Remsima)	Infusion	100 mg	SDL
Insulin Aspart (Novorapid)	Injection, penfill	100 international units/mL	MAF	Type 1 & 2 diabetes mellitus
Insulin Aspart (Novorapid)	Injection, prefilled pen	100 international units/mL	SDL
Insulin Aspart & Insulin Aspart Protamine (Novomix)	Injection, prefilled pen	Insulin Aspart 30% + Insulin Aspart Protamine 70% 100 international units/mL	SDL
Insulin Detemir (Levemir)	Injection, prefilled pen	100 international units/mL	SDL
Insulin Glargine (Lantus)	Injection	100 international units/mL	SDL
Insulin Glargine (Lantus)	Injection, prefilled pen	100 international units/mL	SDL
Insulin Glulisine (Apidra)	Injection, prefilled pen	100 international units/mL	SDL
Insulin Isophane (Human) (Insulatard)	Injection	100 international units/mL	SDL
Insulin Isophane (Human) (Insulatard)	Injection, penfill	100 international units/mL	SDL
Insulin Lispro (Humalog)	Injection	100 international units/mL	MAF	Type 1 & 2 diabetes mellitus
Insulin Lispro (Humalog)	Injection, prefilled pen	100 international units/mL	MAF	Type 1 & 2 diabetes mellitus
Insulin Lispro & Insulin Lispro Protamine (HumalogMix 25)	Injection, penfill	Insulin Lispro 25% + Insulin Lispro Protamine 75% 100 international units/mL	SDL
Insulin Lispro & Insulin Lispro Protamine (HumalogMix 25)	Injection, prefilled pen	Insulin Lispro 25% + Insulin Lispro Protamine 75% 100 international units/mL	MAF	Type 1 & 2 diabetes mellitus
Insulin Lispro & Insulin Lispro Protamine (HumalogMix 50)	Injection, prefilled pen	Insulin Lispro 50% + Insulin Lispro Protamine 50% 100 international units/mL	MAF	Type 1 & 2 diabetes mellitus
Insulin Soluble & Insulin Isophane (Human) (Mixtard)	Injection	Insulin Soluble 30% + Insulin Isophane 70% 100 international units/mL	SDL
Insulin Soluble & Insulin Isophane (Human) (Mixtard)	Injection, penfill	Insulin Soluble 30% + Insulin Isophane 70% 100 international units/mL	SDL
Insulin Soluble (Human) (Actrapid)	Injection	100 international units/mL	SDL
Insulin Soluble (Human) (Actrapid)	Injection, penfill	100 international units/mL	SDL
Interferon Alfa-2a	Injection	3 million international units/0.5 mL	SDL
Intraperitoneal Dialysis	Solution	Dextrose 1.5%, 2.5% or 4.25% with Ca²⁺ 1.25 mmol/L, Na⁺ 132 mmol/L, Mg²⁺ 0.25 mmol/L, Cl^- 95 mmol/L, Lactate 40 mmol/L; Dextrose 1.5%, 2.5% or 4.25% with Ca²⁺ 2.57 mmol/L, Na⁺ 132 mmol/L, Mg²⁺ 0.25 mmol/L, Cl^- 96 mmol/L, Lactate 40 mmol/L	SDL
Iodine	Topical solution	0.5%, 1.0%, 2.5%	SDL
Iodine Aqueous	Oral solution	Iodine 5% + Potassium iodide 10%	SDL
Ipilimumab (Yervoy)	Concentrate for infusion	50 mg/10 mL	MAF	1) Ipilimumab in combination with nivolumab for untreated intermediate- or poor-risk advanced renal cell carcinoma. The doses of nivolumab and ipilimumab should not exceed: 3mg/kg nivolumab and 1mg/kg ipilimumab every 3 weeks for 4 doses. 2) Ipilimumab in combination with nivolumab for the treatment of advanced unresectable or metastatic malignant melanoma. The doses of nivolumab and ipilimumab should not exceed: 1mg/kg nivolumab and 3mg/kg ipilimumab every 3 weeks for 4 doses.
Ipratropium Bromide	Inhalation aerosol	20 mcg/dose	SDL
Ipratropium Bromide	Nebulisation solution	0.025%	SDL
Irinotecan Hydrochloride Trihydrate	Concentrate for infusion	100 mg/5 mL	SDL
Iron (as Polymaltose)	Capsule	100 mg	SDL
Iron (as Polymaltose)	Oral drops	50 mg/mL	SDL
Iron (as Polymaltose)	Tablet	100 mg	SDL
Iron (as Sucrose)	Injection	100 mg/5 mL	SDL
Isoniazid	Tablet	100 mg, 300 mg	SDL
Isoprenaline Hydrochloride	Injection	0.2 mg/mL, 1 mg/mL	SDL
Isoprenaline Sulfate	Injection	0.2 mg/mL, 1 mg/mL	SDL
Isosorbide Dinitrate	Tablet	10 mg	SDL
Isosorbide Mononitrate	Sustained-release tablet	60 mg	SDL
Itraconazole	Capsule	100 mg	SDL
Itraconazole	Oral solution	10 mg/mL	MAF	For prophylaxis of invasive fungal infections in high risk patients (such as anticipated to have prolonged neutropenia) and haematopoietic stem cell transplant recipients
Ivabradine	Tablet	5 mg, 7.5 mg	MAF	Treatment of chronic heart failure in patients with New York Heart Association (NYHA) class II to IV stable chronic heart failure with systolic dysfunction (LVEF of 35% or less), and who are in sinus rhythm with a heart rate of 75 bpm or more, and who are given concomitant standard medical management including the maximum tolerated dose of beta-blocker therapy, angiotensin converting enzyme inhibitors and aldosterone antagonists, unless contraindicated or not tolerated
Ixazomib	Capsule	3 mg, 4 mg	MAF	Ixazomib in combination with lenalidomide and dexamethasone for patients with multiple myeloma who have received at least one prior therapy.
Ixekizumab (Taltz)	Injection, prefilled pen	80 mg/mL	MAF	Additional clinical criteria applies 1) Treatment of adult patients with ankylosing spondylitis 2) Treatment of adult patients with psoriatic arthritis 3) Treatment of adult patients with chronic plaque psoriasis

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class
Kanamycin	Injection	1 g	SDL
Kaolin, Magnesium Carbonate (light) & Sodium Bicarbonate	Oral suspension	Kaolin 20% + Magnesium Carbonate (light) 5% + Sodium Bicarbonate 5%	SDL
Ketamine	Injection	100 mg/2 mL, 500 mg/10 mL	SDL
Ketoprofen	Enteric-coated tablet	100 mg	SDL
Ketoprofen	Gel	2.5%	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
L-Arginine	Capsule	500 mg	MAF	1) Treatment of mitochondrial diseases including MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like episodes) 2) Treatment of urea cycle defects
L-Arginine	Injection	4.2 g/20 mL, 5 g/10 mL	MAF	1) Treatment of mitochondrial diseases including MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like episodes) 2) Treatment of urea cycle defects
L-Arginine	Tablet	500 mg	MAF	1) Treatment of mitochondrial diseases including MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like episodes) 2) Treatment of urea cycle defects
L-Asparaginase	Injection	10,000 international units	SDL
L-Citrulline	Capsule	750 mg	MAF	1) Treatment of hyperammonemia secondary to urea cycle disorders (proximal urea cycle defect, ornithine transcarbamylase deficiency or carbamoyl phosphate synthetase deficiency). 2) Acute treatment of mitochondrial diseases including MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like episodes)
L-Citrulline	Powder	5 g	MAF	1) Treatment of hyperammonemia secondary to urea cycle disorders (proximal urea cycle defect, ornithine transcarbamylase deficiency or carbamoyl phosphate synthetase deficiency). 2) Acute treatment of mitochondrial diseases including MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like episodes)
L-Isoleucine	Powder	100 mg/1.5 g	MAF	Treatment of Maple Syrup Urine Disease
L-Valine	Powder	100 mg/1.5 g	MAF	Treatment of Maple Syrup Urine Disease
Lactulose	Syrup	3.3 g/5 mL, 3.35 g/5 mL	SDL
Lamivudine	Tablet	100 mg, 150 mg	SDL
Lamotrigine	Dispersible tablet	5 mg	SDL
Lamotrigine	Tablet	50 mg, 100 mg	SDL
Land Snakes Antivenom	Concentrate for infusion	-	SDL
Lanreotide	Prolonged release injection	60 mg, 90 mg, 120 mg	MAF	1) For the reduction of symptoms associated with carcinoid syndrome. 2) For the improvement of symptoms associated with acromegaly. 3) Treatment of acromegaly in patients with abnormal levels of Growth Hormone (GH) and/or Insulin-like Growth Factor-1 (IGF-1) after surgery and/or radiotherapy or in patients who require medical treatment. 4) Treatment of neuroendocrine tumours of gastrointestinal or pancreatic origin.
Lapatinib	Tablet	250 mg	MAF	1) Lapatinib in combination with an aromatase inhibitor for postmenopausal women with HR positive, HER2 positive metastatic breast cancer. 2) Lapatinib in combination with capecitabine for HER2 positive, advanced or metastatic breast cancer in patients whose disease has progressed after treatment with an anthracycline and, a taxane, and on prior trastuzumab therapy in the metastatic setting.
Latanoprost	Eye drops	0.005%	SDL
Leflunomide	Tablet	20 mg	SDL
Lenalidomide	Capsule	5 mg, 10 mg, 15 mg, 25 mg	SDL
Lenvatinib	Capsule	4 mg, 10 mg	MAF	1) Treatment of advanced unresectable hepatocellular carcinoma in patients with adequate liver function as assessed by the Child-Pugh scoring system, when used according to HSA-recommended dosing regimens. 2) Treatment of locally advanced or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.
Letrozole	Tablet	2.5 mg	SDL
Leuprorelin Acetate	Depot injection	3.75 mg, 11.25 mg	MAF	LHRH agonist is recommended: 1) Treatment of breast cancer where hormone therapy is specified. 2) Treatment of locally advanced or metastatic prostate cancer.
Leuprorelin Acetate	Depot injection, Powder and solvent for solution for injection	7.5 mg, 22.5 mg, 30 mg, 45 mg	MAF	Treatment of locally advanced or metastatic prostate cancer.
Levetiracetam	Concentrate for infusion	100 mg/mL	SDL
Levetiracetam	Oral solution	100 mg/mL	SDL
Levetiracetam	Tablet	250 mg, 500 mg, 1 g	SDL
Levocarnitine	Capsule	500 mg	MAF	Prevention of primary and secondary carnitine deficiency due to detoxification
Levocarnitine	Injection	1 g/5 mL	MAF	Prevention of primary and secondary carnitine deficiency due to detoxification
Levocarnitine	Oral solution	500 mg/10 mL	MAF	Prevention of primary and secondary carnitine deficiency due to detoxification
Levodopa & Benserazide	Capsule	Levodopa 100 mg + Benserazide 25 mg	SDL
Levodopa & Benserazide	Tablet	Levodopa 200 mg + Benserazide 50 mg	SDL
Levodopa & Benserazide	Controlled-release capsule	Levodopa 100 mg + Benserazide 25 mg	SDL
Levodopa & Carbidopa	Tablet	Levodopa 100 mg + Carbidopa 25 mg, Levodopa 250 mg + Carbidopa 25 mg	SDL
Levodopa & Carbidopa	Sustained-release tablet	Levodopa 200 mg + Carbidopa 50 mg	SDL
Levodopa, Carbidopa & Entacapone	Tablet	Levodopa 50 mg + Carbidopa 12.5 mg + Entacapone 200 mg, Levodopa 100 mg + Carbidopa 25 mg + Entacapone 200 mg, Levodopa 150 mg + Carbidopa 37.5 mg + Entacapone 200 mg, Levodopa 200 mg + Carbidopa 50 mg + Entacapone 200 mg	SDL
Levonorgestrel & Ethinylestradiol	Tablet	Levonorgestrel 0.15 mg + Ethinylestradiol 0.03 mg	SDL
Levothyroxine Sodium	Tablet	25 mcg, 50 mcg, 75 mcg, 100 mcg	SDL
Lidocaine	Ointment	5%	SDL
Lidocaine	Topical solution	4%	SDL
Lidocaine	Topical spray	10%	SDL
Lidocaine & Adrenaline	Injection	Lidocaine 2% + Adrenaline 1:80,000 (12.5 microgram/mL)	SDL
Lidocaine & Prilocaine	Cream	Lidocaine 2.5% + Prilocaine 2.5%	SDL
Lidocaine Hydrochloride	Gel	2%	SDL
Lidocaine Hydrochloride	Injection	1%	SDL
Lidocaine Hydrochloride	Oral solution (viscous)	2%	SDL
Lidocaine Hydrochloride	Injection (preservative-free)	1%, 2%	SDL
Lidocaine Hydrochloride	Solution for injection in pre-filled syringe	100 mg/ 10 mL, 200 mg/ 10mL	SDL
Linagliptin	Tablet	5 mg	MAF	For patients with type 2 diabetes mellitus and chronic kidney disease stages 3b, 4 or 5
Linezolid	Infusion	600 mg/3 mL	SDL
Linezolid	Tablet	600 mg	SDL
Liothyronine	Tablet	20 mcg	SDL
Liquid Paraffin	Oral emulsion	2.5 mL/5 mL	SDL
Liquid Paraffin	Liquid	-	SDL
Lisinopril	Tablet	5 mg, 10 mg, 20 mg	SDL
Lithium Carbonate	Controlled-release tablet	400 mg	SDL
Lomustine	Capsule	10 mg, 40 mg	SDL
Lopinavir & Ritonavir	Oral solution	Lopinavir 80 mg/mL + Ritonavir 20 mg/mL	SDL
Lopinavir & Ritonavir	Tablet	Lopinavir 200 mg + Ritonavir 50 mg	SDL
Loratadine	Syrup	5 mg/5 mL	SDL
Loratadine	Tablet	10 mg	SDL
Lorazepam	Tablet	0.5 mg, 1 mg	SDL
Lorlatinib	Tablet	25 mg, 100 mg	MAF	Treatment of locally advanced or metastatic ALK mutation-positive non-small-cell lung cancer.
Losartan Potassium	Tablet	50 mg, 100 mg	SDL
Losartan Potassium & Hydrochlorothiazide	Tablet	Losartan 50 mg + Hydrochlorothiazide 12.5 mg, Losartan 100 mg + Hydrochlorothiazide 25 mg	SDL
Lovastatin	Tablet	20 mg	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Magnesium Carbonate & Sodium Bicarbonate	Oral suspension	Magnesium Carbonate 150 mg/5 mL + Sodium Bicarbonate 250 mg/5 mL + Aromatic Cardamom Tincture 0.15 mL/5 mL	SDL
Magnesium Chloride Hexahydrate, Potassium Chloride & Procaine Hydrochloride	Concentrate for infusion	Magnesium Chloride Hexahydrate 162.5 mg/mL (0.8 mmol/mL) + Potassium Chloride 59.5 mg/mL (0.8 mmol/mL) + Procaine Hydrochloride 13.64 mg/mL (0.05 mmol/mL)	SDL
Magnesium Sulfate	Crystal	-	SDL
Magnesium Sulfate	Injection	49.3%	SDL
Magnesium Sulfate	Injection	49.3% (2 mmol Mg2+/mL)	SDL
Magnesium Sulfate & Glycerin	Syrup	Magnesium Sulfate 35.4% + Glycerin 1.1%	SDL
Magnesium Trisilicate	Oral suspension	Magnesium Trisilicate 5% + Magnesium Carbonate 5% + Sodium Bicarbonate 5%	SDL
Malathion	Lotion	0.5%	SDL
Mannitol	Infusion	20%	SDL
Mebeverine Hydrochloride	Tablet	135 mg	SDL
Medroxyprogesterone Acetate	Injection	50 mg/mL	SDL
Medroxyprogesterone Acetate	Tablet	5 mg, 10 mg	SDL
Mefenamic Acid	Capsule	250 mg	SDL
Mefloquine	Tablet	250 mg	SDL
Megestrol	Tablet	40 mg, 160 mg	SDL
Melphalan	Injection	50 mg	SDL
Melphalan	Tablet	2 mg	SDL
Memantine	Tablet	10 mg	SDL
Mercaptopurine	Tablet	50 mg	SDL
Meropenem	Injection	500 mg, 1 g	SDL
Mesalazine	Enema	2 g/30 mL	SDL
Mesalazine	Enteric-coated tablet	250 mg, 400 mg, 500 mg, 800 mg	SDL
Mesalazine	Granules	2 g, 4 g	SDL
Mesalazine	Prolonged-release tablet	500 mg, 1 g	SDL
Mesalazine	Suppository	250 mg, 500 mg, 1 g	SDL
Mesna	Injection	100 mg/mL	SDL
Mesna	Tablet	400 mg, 600 mg	SDL
Metformin Hydrochloride	Tablet	250 mg, 500 mg, 850 mg	SDL
Methadone	Tablet	5 mg	SDL
Methionine	Oral powder	-	SDL
Methotrexate	Injection	50 mg/2 mL, 1 g/10 mL	SDL
Methotrexate	Injection (preservative-free)	50 mg/2 mL	SDL
Methotrexate	Tablet	2.5 mg	SDL
Methoxsalen	Lotion	0.01%, 0.05%, 0.1%, 0.75%	SDL
Methoxsalen	Capsule	10 mg	SDL
Methoxsalen	Tablet	10 mg	SDL
Methoxy polyethylene glycol-epoetin beta (Mircera)	Prefilled syringe	50 mcg/0.3 mL, 75 mcg/0.3 mL, 100 mcg/0.3 mL	SDL
Methyl Salicylate	Cream	10%-20%	SDL
Methyl Salicylate	Solution	25%	SDL
Methylated Spirit	Topical solution	70%	SDL
Methyldopa	Tablet	125 mg, 250 mg	SDL
Methylphenidate Hydrochloride	Extended-release tablet	18 mg, 27 mg, 36 mg, 54 mg	MAF	Attention deficit hyperactivity disorder in children and adolescents aged < 18 years old
Methylphenidate Hydrochloride	Long-acting capsule	20 mg	MAF	Attention deficit hyperactivity disorder in children and adolescents aged < 18 years old
Methylphenidate Hydrochloride (Medikinet)	Modified-release capsule	5 mg, 10 mg, 20 mg, 30 mg, 40 mg	SDL
Methylphenidate Hydrochloride	Sustained-release tablet	20 mg	MAF	Attention deficit hyperactivity disorder in children and adolescents aged < 18 years old
Methylphenidate Hydrochloride	Tablet	10 mg	SDL
Methylprednisolone (as Sodium Succinate)	Injection	62.5 mg/mL	SDL
Metoclopramide Hydrochloride	Injection	5mg/mL	SDL
Metoclopramide Hydrochloride	Tablet	10 mg	SDL
Metronidazole	Infusion	5 mg/mL	SDL
Metronidazole	Tablet	200 mg	SDL
Miconazole	Oral gel	2%	SDL
Miconazole Nitrate	Cream	2%	SDL
Midazolam	Injection	5 mg/mL, 5 mg/5 mL	SDL
Midodrine Hydrochloride	Tablet	5 mg	SDL
Midostaurin	Capsule	25 mg	MAF	Treatment of FLT-3-mutation positive acute myeloid leukaemia (AML) in combination with standard intensive induction and consolidation chemotherapy. Standard induction chemotherapy must include cytarabine and an anthracycline. Midostaurin is not recommended for maintenance therapy.
Mirtazapine	Oral disintegrating tablet	15 mg, 30 mg	SDL
Mirtazapine	Tablet	30 mg	SDL
Mitomycin	Injection	2 mg, 10 mg	SDL
Mitoxantrone	Injection	20 mg/10 mL	SDL
Moclobemide	Tablet	150 mg	SDL
Mometasone Furoate	Nasal spray	0.05%	SDL
Montelukast	Tablet	10 mg	SDL
Morphine Sulfate	Controlled-release tablet	10 mg, 30 mg	SDL
Morphine Sulfate	Injection	10 mg/mL	SDL
Morphine	Oral solution	1 mg/mL, 2 mg/mL	SDL
Morphine	Syrup	1 mg/mL, 2 mg/mL	SDL
Multivitamin for Paediatrics	Oral solution	A combination preparation of vitamins, minerals and/or nutrients, which includes at least 3 of the following: Ascorbic acid, Riboflavine, Nicotinamide, Thiamine, Pyridoxine, Calciferol, Cyanocobalamin, Vitamin A	SDL
Mycophenolate Mofetil	Capsule	250 mg	SDL
Mycophenolate Mofetil	Infusion	500 mg	SDL
Mycophenolate Mofetil	Tablet	500 mg	SDL
Mycophenolate Mofetil	Oral suspension	1000 mg/5 mL	SDL
Mycophenolate Sodium	Enteric-coated Tablet	180 mg, 360 mg	MAF	Prevention of organ rejection in patients who have received a kidney transplant and are unable to tolerate mycophenolate mofetil due to gastrointestinal adverse effects

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Naloxone Hydrochloride	Injection	0.4 mg/mL	SDL
Nandrolone Decanoate	Injection	25 mg/mL	SDL
Naphazoline Hydrochloride & Pheniramine Maleate	Eye drops	Naphazoline Hydrochloride 0.025% + Pheniramine Maleate 0.3%	SDL
Neomycin Sulfate	Tablet	500 mg	SDL
Neomycin, Polymyxin B & Dexamethasone	Ear drops	Neomycin Sulfate 6,500 international units/mL + Polymyxin B Sulfate 10,000 international units/mL + Dexamethasone Sodium Metasulfobenzoate 1 mg/mL	SDL
Neostigmine Metilsulfate	Injection	2.5 mg/mL	SDL
Netupitant & Palonosetron	Capsule	Netupitant 300 mg & Palonosetron 0.5 mg	MAF	Prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
Nevirapine	Extended-release tablet	400 mg	SDL
Nevirapine	Tablet	200 mg	SDL
Nicotine (Nicorette)	Chewing gum	2 mg, 4 mg	MAF	As an aid for smoking cessation in patients who are willing to quit and enrolled in a smoking cessation counselling program, with a documented Fagerstrom score of three and above. The smoking cessation counselling programme should include a minimum of three counselling sessions, and counselling should be delivered by a healthcare professional trained in smoking cessation counselling, at an approved setting. Nicotine replacement therapies should not be used in combination with varenicline for smoking cessation
Nicotine (Nicotinell)	Lozenge	1 mg	MAF	As an aid for smoking cessation in patients who are willing to quit and enrolled in a smoking cessation counselling program, with a documented Fagerstrom score of three and above. The smoking cessation counselling programme should include a minimum of three counselling sessions, and counselling should be delivered by a healthcare professional trained in smoking cessation counselling, at an approved setting. Nicotine replacement therapies should not be used in combination with varenicline for smoking cessation.
Nicotine (Nicotinell)	Transdermal patch	7 mg/ 24 hours, 14 mg/ 24 hours, 21 mg/ 24 hours	MAF	As an aid for smoking cessation in patients who are willing to quit and enrolled in a smoking cessation counselling program, with a documented Fagerstrom score of three and above. The smoking cessation counselling programme should include a minimum of three counselling sessions, and counselling should be delivered by a healthcare professional trained in smoking cessation counselling, at an approved setting. Nicotine replacement therapies should not be used in combination with varenicline for smoking cessation.
Nicotinic Acid	Tablet	50 mg	SDL
Nifedipine	Extended-release tablet	30 mg, 60 mg	SDL
Nifedipine	Tablet	10 mg	SDL
Nifedipine	Capsule	5 mg, 10 mg	SDL
Nilotinib	Capsule	50 mg, 150 mg, 200 mg	MAF	1) Treatment of newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase. 2) Treatment of adults with treatment-resistant or treatment-intolerant chronic myeloid leukaemia (CML) in chronic phase or accelerated phase; or children with treatment-resistant or treatment-intolerant CML in chronic phase.
Niraparib	Tablet	100 mg	MAF	Maintenance monotherapy for patients with advanced epithelial high-grade ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with BRCA mutation and/or homologous recombination deficiency (HRD) positive status. Treatment should be continued until disease progression or unacceptable toxicity or a maximum of 36 months.
Nitrazepam	Tablet	5 mg	SDL
Nitrofurantoin	Tablet	50 mg	SDL
Nivolumab (Opdivo)	Concentrate for infusion	40 mg/4 mL, 100 mg/10 mL	MAF	1) For intermediate- or poor-risk advanced renal cell carcinoma, following induction treatment with nivolumab in combination with ipilimumab. Nivolumab should be given as a weight-based dose up to a maximum of 240 mg every two weeks or 480 mg every four weeks. 2) For previously treated advanced renal cell carcinoma (RCC). Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for advanced RCC. Nivolumab should be given as a weight-based dose up to a maximum of 240 mg every two weeks or 480 mg every four weeks. 3) Nivolumab in combination with ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma. The doses of nivolumab and ipilimumab should not exceed: 3mg/kg nivolumab and 1mg/kg ipilimumab every 3 weeks for 4 doses. 4) Adjuvant treatment of completely resected malignant melanoma in patients with lymph node involvement. Nivolumab should be given as a weight-based dose up to a maximum of 240 mg every two weeks or 480 mg every four weeks. Maximum duration of treatment: 12 months. 5) Monotherapy for advanced unresectable or metastatic malignant melanoma. Patients must not have received prior treatment with a PD-1 inhibitor or ipilimumab for advanced unresectable or metastatic malignant melanoma. Nivolumab should be given as a weight-based dose up to a maximum of 240 mg every two weeks or 480 mg every four weeks. 6) For patients with recurrent or metastatic squamous cell cancer of the head and neck whose disease progressed within six months of starting platinum-based chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for this condition in the recurrent or metastatic setting. Nivolumab should be given as a weight-based dose up to a maximum of 240 mg every two weeks or 480 mg every four weeks. 7) Treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for metastatic NSCLC. Nivolumab should be given as a weight-based dose up to a maximum of 240 mg every two weeks or 480 mg every four weeks. 8) Treatment of patients with unresectable locally advanced or recurrent gastric or gastroesophageal junction (GEJ) adenocarcinoma after 2 or more prior systemic therapies. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for unresectable locally advanced or recurrent gastric or GEJ cancer. Nivolumab should be given as a weight-based dose up to a maximum of 240 mg every two weeks or 480 mg every four weeks. 9) Treatment of patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after an autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for this condition in the relapsed or refractory setting. Nivolumab should be given as a weight-based dose up to a maximum of 240 mg every two weeks or 480 mg every four weeks. 10) Adjuvant treatment of completely resected oesophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy. Maximum treatment duration: 12 months. 11) Nivolumab in combination with fluoropyrimidine and platinum-based chemotherapy for untreated, unresectable advanced or metastatic HER2 negative gastric cancer, gastroesophageal junction cancer or oesophageal adenocarcinoma. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses. 12) Treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for this condition in the unresectable advanced, recurrent or metastatic setting. 13) Nivolumab in combination with ipilimumab for the treatment of advanced unresectable or metastatic malignant melanoma. The doses of nivolumab and ipilimumab should not exceed: 1mg/kg nivolumab and 3mg/kg ipilimumab every 3 weeks for 4 doses. 14) Treatment of advanced unresectable or metastatic malignant melanoma, following induction treatment with nivolumab in combination with ipilimumab. Nivolumab should be given as a weight-based dose up to a maximum of 240 mg every two weeks or 480 mg every four weeks. 15) Nivolumab in combination with fluoropyrimidine and platinum-based chemotherapy for untreated, unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses.
Nivolumab	Concentrate for infusion	240 mg/24 mL	MAF	1) Adjuvant treatment of completely resected oesophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy. Maximum treatment duration: 12 months. 2) Nivolumab in combination with fluoropyrimidine and platinum-based chemotherapy for untreated, unresectable advanced or metastatic HER2 negative gastric cancer, gastroesophageal junction cancer or oesophageal adenocarcinoma. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses. 3) Treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for this condition in the unresectable advanced, recurrent or metastatic setting. 4) Nivolumab in combination with ipilimumab for the treatment of advanced unresectable or metastatic malignant melanoma. The doses of nivolumab and ipilimumab should not exceed: 1mg/kg nivolumab and 3mg/kg ipilimumab every 3 weeks for 4 doses. 5) Treatment of advanced unresectable or metastatic malignant melanoma, following induction treatment with nivolumab in combination with ipilimumab. The dose of nivolumab should not exceed 3 mg/kg every 2 weeks. 6) Nivolumab in combination with fluoropyrimidine and platinum-based chemotherapy for untreated, unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses.
Norepinephrine	Concentrate for infusion	4 mg/4 mL	SDL
Norethisterone	Tablet	5 mg	SDL
Nortriptyline	Capsule	10 mg, 25 mg	SDL
Nystatin	Oral suspension	100,000 units/mL	SDL
Nystatin	Vaginal tablet	100,000 units	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Obinutuzumab (Gazyva)	Concentrate for infusion	1000 mg/40 mL	MAF	1) Obinutuzumab in combination with bendamustine, for the treatment of follicular lymphoma that has not responded to or progressed within 6 months after treatment with rituximab or a rituximab-containing regimen. Patients must not have received obinutuzumab for follicular lymphoma. Maintenance treatment with obinutuzumab should be stopped at 2 years, or earlier if disease progresses. 2) Obinutuzumab in combination with venetoclax for patients with previously untreated chronic lymphocytic leukaemia (CLL) who are unsuitable for fludarabine-based therapy. Maximum treatment duration of obinutuzumab is 6 cycles and venetoclax is 12 months.
Octreotide	Depot Injection	20 mg, 30 mg	SDL
Olanzapine	Oral disintegrating tablet	5 mg, 10 mg	SDL
Olanzapine	Tablet	5 mg, 10 mg	SDL
Olaparib	Tablet	100 mg, 150 mg	MAF	1) Maintenance monotherapy for patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Treatment should be continued until disease progression or unacceptable toxicity or a maximum of 24 months. 2) Maintenance monotherapy for patients with platinum-sensitive relapsed BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Patients must not have received prior treatment with a PARP inhibitor for ovarian cancer. Treatment should be continued until disease progression or unacceptable toxicity. 3) Olaparib in combination with bevacizumab biosimilar (subsidised brand) as maintenance treatment of patients with advanced homologous recombination deficiency (HRD) positive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy in combination with bevacizumab biosimilar. Treatment with olaparib should be continued until disease progression or unacceptable toxicity or for a maximum of 24 months. 4) Treatment of germline BRCA-mutated, HER2 negative, locally advanced or metastatic breast cancer in patients previously treated with chemotherapy. 5) Maintenance treatment of patients with deleterious or suspected deleterious germline BRCA mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. 6) Treatment of patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene BRCA1/2 and/or ATM-mutations (germline and/or somatic) whose disease has progressed following prior treatment with abiraterone or a second-generation anti-androgen. Androgen deprivation therapy (ADT) should be continued. 7) Adjuvant treatment of patients with germline BRCA-mutated, HER2- negative, high-risk early breast cancer who have previously been treated with neoadjuvant or adjuvant chemotherapy. Maximum duration of treatment: 1 year.
Olive Oil	Ear drops	-	SDL
Omalizumab (Xolair)	Injection	150 mg	MAF	Additional clinical criteria applies As an add-on therapy to H₁-antihistamines for treating severe chronic spontaneous urticaria (CSU) in patients aged 12 years and older, with a mean weekly Urticaria Activity Score (UAS7) of 28 and above, despite the use of, or who are intolerant to, four-times registered dose of second generation non-sedating H₁-antihistamines. A maximum of six 300 mg doses of omalizumab should be administered for each treatment course. Re-treatment with omalizumab can be considered upon relapse for patients who achieve an adequate response during the previous treatment course. Adequate response to omalizumab is defined as a UAS7 score of six or below while on treatment.
Omalizumab (Xolair)	Prefilled syringe	150 mg/mL	MAF	Additional clinical criteria applies As an add-on therapy to H₁-antihistamines for treating severe chronic spontaneous urticaria (CSU) in patients aged 12 years and older, with a mean weekly Urticaria Activity Score (UAS7) of 28 and above, despite the use of, or who are intolerant to, four-times registered dose of second generation non-sedating H₁-antihistamines. A maximum of six 300 mg doses of omalizumab should be administered for each treatment course. Re-treatment with omalizumab can be considered upon relapse for patients who achieve an adequate response during the previous treatment course. Adequate response to omalizumab is defined as a UAS7 score of six or below while on treatment.
Omeprazole	Capsule	20 mg	SDL
Omeprazole	Injection	40mg	SDL
Ondansetron	Injection	2 mg/mL	SDL
Ondansetron	Tablet	8 mg	SDL
Oral Rehydration Salts	Effervescent tablet	-	SDL
Oral Rehydration Salts	Oral powder for reconstitution	-	SDL
Osimertinib	Tablet	40 mg, 80 mg	MAF	Treatment of patients with locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer whose disease has progressed on or after EGFR TKI therapy. For patients with isolated brain metastases who are clinically ineligible for re-biopsy and where T790M cannot be confirmed, osimertinib may be used until progression.
Oxaliplatin	Injection	50 mg, 100 mg, 200 mg	SDL
Oxybutynin Chloride	Tablet	5 mg	SDL
Oxycodone Hydrochloride	Capsule	5 mg, 10 mg	MAF	For the management of moderate to severe cancer pain when other opioids (e.g., morphine/fentanyl) is contraindicated or not effective.
Oxymetazoline Hydrochloride	Nasal drops	0.01%, 0.025%, 0.05%	SDL
Oxymetazoline Hydrochloride	Nasal spray	0.025%, 0.05%	SDL
Oxytocin	Injection	10 international units/mL	SDL
Oxytocin & Ergometrine Maleate	Injection	Oxytocin 5 international units/mL + Ergometrine Maleate 0.5 mg/mL	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Paclitaxel	Concentrate for infusion	150 mg/25 mL, 300 mg/50 mL	SDL
Paclitaxel (albumin-bound nanoparticles)	Infusion	100 mg	MAF	1) Nab-paclitaxel in combination with gemcitabine, for treatment of locally advanced or metastatic adenocarcinoma of the pancreas. 2) Monotherapy for metastatic breast cancer in patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated. 3) Nab-paclitaxel in combination with carboplatin, for previously untreated locally advanced or metastatic non-small cell lung cancer in patients who are not candidates for curative surgery or radiation therapy. 4) For cancer treatment in patients who are intolerant to paclitaxel.
Palbociclib	Capsule	75 mg, 100 mg, 125 mg	MAF	1) Palbociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for HR positive, HER2 negative, advanced or metastatic breast cancer. Pre/perimenopausal women treated with this combination could also receive a luteinizing hormone-releasing hormone agonist according to local clinical practice. 2) Palbociclib in combination with fulvestrant for treating HR positive, HER2 negative, advanced or metastatic breast cancer in patients who have received prior endocrine therapy. Pre/perimenopausal women treated with this combination could also receive a luteinizing hormone-releasing hormone agonist according to local clinical practice.
Palbociclib	Tablet	75 mg, 100 mg, 125 mg	MAF	1) Palbociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for HR positive, HER2 negative, advanced or metastatic breast cancer. Pre/perimenopausal women treated with this combination could also receive a luteinizing hormone-releasing hormone agonist according to local clinical practice. 2) Palbociclib in combination with fulvestrant for treating HR positive, HER2 negative, advanced or metastatic breast cancer in patients who have received prior endocrine therapy. Pre/perimenopausal women treated with this combination could also receive a luteinizing hormone-releasing hormone agonist according to local clinical practice.
Pamidronate Disodium	Infusion	30 mg, 90 mg	MAF	1) Treatment of metastatic bone lesions from breast cancer and advanced multiple myeloma 2) Treatment of hypercalcaemia of malignancy
Pancuronium Bromide	Concentrate for infusion	2 mg/mL	SDL
Panitumumab (Vectibix)	Concentrate for infusion	100 mg/5 mL	SDL
Pantoprazole	Injection	40 mg	SDL
Paracetamol	Infusion	500 mg/50 mL, 1,000 mg/100 mL	SDL
Paracetamol	Oral suspension	120 mg/5 mL, 250 mg/5 mL	SDL
Paracetamol	Rectal suppository	125 mg, 250 mg, 325 mg, 650 mg	SDL
Paracetamol	Tablet	120 mg, 500 mg	SDL
Paracetamol & Orphenadrine Citrate	Tablet	Paracetamol 450 mg + Orphenadrine Citrate 35 mg	SDL
Paraffin	Liquid	-	SDL
Paraffin Soft & Paraffin Liquid	Emulsion	Soft Paraffin 50% + Liquid Paraffin 50%	SDL
Paraffin Soft & Paraffin Liquid	Ointment	Soft Paraffin 60% + Liquid Paraffin 40%	SDL
Pazopanib	Tablet	200 mg, 400 mg	SDL
Pegaspargase (Oncaspar)	Injection/ infusion	750 U/ml	SDL
Pegfilgrastim (Neulastim)	Prefilled syringe	6 mg/0.6 mL	SDL
Pegfilgrastim biosimilar (Fulphila)	Prefilled syringe	6 mg/0.6 mL	SDL
Peginterferon Alfa-2a (Pegasys)	Prefilled syringe	135 mcg/0.5 mL, 180 mcg/0.5 mL	SDL
Pembrolizumab (Keytruda)	Infusion	100 mg/4 mL	MAF	1) For untreated metastatic non-small cell lung cancer (NSCLC) in patients whose tumours express PD-L1 with a tumour proportion score ≥50%, with no EGFR or ALK genomic tumour aberrations. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. Pembrolizumab retreatment is allowed at time of progression for up to 1 additional year if the initial treatment was stopped for reasons other than disease progression. 2) Pembrolizumab in combination with platinum-doublet chemotherapy, for untreated metastatic non-squamous non-small cell lung cancer (NSCLC) in patients with no EGFR or ALK genomic tumour aberrations. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. Pembrolizumab retreatment is allowed at time of progression for up to 1 additional year if the initial treatment was stopped for reasons other than disease progression. 3) Pembrolizumab in combination with platinum-doublet chemotherapy for untreated metastatic squamous non-small cell lung cancer (NSCLC). Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. Pembrolizumab retreatment is allowed at time of progression for up to 1 additional year if the initial treatment was stopped for reasons other than disease progression. 4) Treatment of patients with metastatic non-small cell lung cancer (NSCLC), whose tumours express PD-L1 with a tumour proportion score ≥1% and had disease progression during or following platinum-containing chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for metastatic NSCLC. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. Pembrolizumab retreatment is allowed at time of progression for up to 1 additional year if the initial treatment was stopped for reasons other than disease progression. 5) Adjuvant treatment of completely resected malignant melanoma in patients with lymph node involvement. Maximum duration of treatment: 12 months. 6) Treatment of advanced unresectable or metastatic malignant melanoma. Patients must not have received a PD-1 inhibitor or ipilimumab for advanced unresectable or metastatic malignant melanoma. 7) Monotherapy for untreated unresectable, recurrent or metastatic squamous cell cancer of the head and neck (RMSCCHN) with PD-L1 CPS≥1. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. Pembrolizumab retreatment is allowed at time of progression for up to 1 additional year if the initial treatment was stopped for reasons other than disease progression. 8) Pembrolizumab in combination with platinum-based chemotherapy, for untreated unresectable, recurrent or metastatic squamous cell cancer of the head and neck (RMSCCHN) with PD-L1 CPS≥1. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. Pembrolizumab retreatment is allowed at time of progression for up to 1 additional year if the initial treatment was stopped for reasons other than disease progression. 9) Treatment of patients with relapsed or refractory classical Hodgkin lymphoma (cHL), who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for this condition in the relapsed or refractory setting. Treatment with pembrolizumab should be stopped at 2 years, or earlier if the person has a stem cell transplant or the disease progresses. Pembrolizumab retreatment is allowed at time of progression for up to 1 additional year if the initial treatment was stopped for reasons other than disease progression. 10) Treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) after receiving platinum-containing chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for locally advanced or metastatic UC. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. Pembrolizumab retreatment is allowed at time of progression for up to 1 additional year if the initial treatment was stopped for reasons other than disease progression. 11) Pembrolizumab in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple negative breast cancer whose tumours express PD-L1 (CPS ≥10) and who have not received prior chemotherapy for metastatic disease. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. Pembrolizumab retreatment is allowed at time of progression for up to 1 additional year if the initial treatment was stopped for reasons other than disease progression. 12) For untreated metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. Pembrolizumab retreatment is allowed at time of progression for up to 1 additional year if the initial treatment was stopped for reasons other than disease progression. 13) Pembrolizumab in combination with fluoropyrimidine and platinum-based chemotherapy for untreated, locally advanced unresectable or metastatic carcinoma of the oesophagus or HER2 negative gastroesophageal junction (GEJ) adenocarcinoma (tumours with epicenter 1 to 5 cm above the GEJ) that is not amenable to surgical resection or definitive chemoradiation. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses.
Pemetrexed	Injection	100 mg, 500 mg	SDL
Penicillamine	Capsule	250 mg	SDL
Pethidine Hydrochloride	Injection	50 mg/mL	SDL
Phenazopyridine Hydrochloride	Tablet	100 mg	SDL
Phenobarbital Sodium	Injection	200 mg/mL	SDL
Phenobarbitone	Tablet	10 mg, 30 mg, 60 mg	SDL
Phenol (in almond oil)	Injection	5%	SDL
Phenoxymethylpenicillin	Tablet	250 mg	SDL
Phenylephrine Hydrochloride	Single-use eye drops	2.5%, 10%	SDL
Phenylephrine Hydrochloride	Eye drops	2.5%, 10%	SDL
Phenytoin	Oral suspension	125 mg/5 mL	SDL
Phenytoin Sodium	Injection	50 mg/mL	SDL
Phenytoin Sodium	Capsule	30 mg, 100 mg	SDL
Physostigmine Salicylate	Injection	1 mg/mL, 2 mg/5 mL	SDL
Phytomenadione	Injection	10 mg/mL, 2 mg/0.2 mL	SDL
Pilocarpine Hydrochloride	Eye drops	2%, 4%	SDL
Pilocarpine Nitrate	Single-use eye drops	2%	SDL
Piperacillin & Tazobactam	Injection	Piperacillin 4 g + Tazobactam 0.5 g	SDL
Piroxicam	Capsule	10 mg, 20 mg	SDL
Plasma-derived Factor VIII	Injection	250 international units, 500 international units, 1000 international units	SDL
Plasma-derived Factor VIII & Von Willebrand Factor	Injection	Plasma-derived Factor VIII 250 international units, 500 international units, 1000 international units + Von Willebrand Factor range 100 international units to 3200 international units	SDL
Podophyllum Resin	Paint	0.25%, 0.5%	SDL
Polatuzumab vedotin (Polivy)	Powder for concentrate for solution for infusion	30 mg, 140 mg	MAF	Polatuzumab in combination with rituximab biosimilar (subsidised brand), cyclophosphamide, doxorubicin, and prednisone for previously untreated diffuse large B-cell lymphoma (DLBCL) in patients with an international prognostic index (IPI) score of 3 to 5.
Pomalidomide	Capsule	1 mg, 2 mg, 3 mg, 4 mg	MAF	1) Pomalidomide in combination with bortezomib or cyclophosphamide, plus dexamethasone, for patients with multiple myeloma who have received at least one prior therapy. 2) Pomalidomide in combination with dexamethasone for patients with multiple myeloma who have received at least two prior therapies, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.
Ponatinib	Tablet	15 mg	MAF	1) Treatment of chronic, accelerated, or blast phase chronic myeloid leukaemia (CML) in patients: • whose disease is resistant to imatinib or dasatinib or nilotinib, and who have the T315I mutation OR • whose disease is resistant to both nilotinib and dasatinib OR • whose disease is resistant to nilotinib or dasatinib and who are intolerant of/contraindicated to the other drug. 2) Treatment of patients with Philadelphia chromosome positive acute lymphoblastic leukaemia who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.
Poractant alfa	Intratracheal suspension	120 mg/1.5 mL	SDL
Posaconazole	Delayed-release tablet	100 mg	SDL
Posaconazole	Oral suspension	40 mg/mL	MAF	For prophylaxis of invasive fungal infections in high risk patients (such as anticipated to have prolonged neutropenia) and haematopoietic stem cell transplant recipients
Potassium Chloride	Slow-release tablet	600 mg	SDL
Potassium Chloride	Oral solution	500 mg/5 mL	SDL
Potassium Chloride	Concentrate for infusion	7.45%	SDL
Potassium Chloride	Infusion	0.1 mmol/mL, 0.2 mmol/mL, 0.4 mmol/mL	SDL
Potassium Chloride & Sodium Chloride	Infusion	Potassium Chloride 0.15% + Sodium Chloride 0.9%	SDL
Potassium Citrate	Oral solution	500 mg/5 mL	SDL
Potassium Permanganate	Crystals	100%	SDL
Potassium Permanganate	Topical solution	0.1%	SDL
Potassium Phosphate Monobasic	Concentrate for infusion	1 mmol/mL (0.1361 g/mL)	SDL
Povidone-Iodine	Topical solution	10%	SDL
Pralidoxime Chloride	Injection	500 mg/10 mL	SDL
Pramipexole Dihydrochloride Monohydrate	Tablet	0.125 mg, 1 mg	SDL
Pravastatin Sodium	Tablet	20 mg	SDL
Prazosin	Tablet	1 mg, 5 mg	SDL
Prednisolone	Syrup	10 mg/5 mL	SDL
Prednisolone	Tablet	1 mg, 5 mg, 20 mg	SDL
Pregabalin	Capsule	25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 300 mg	SDL
Primaquine	Tablet	7.5 mg, 15 mg	SDL
Probenecid	Tablet	500 mg	SDL
Procainamide Hydrochloride	Injection	100 mg/mL	SDL
Procaine Hydrochloride	Lotion (in spirit 70%)	2%	SDL
Procarbazine	Capsule	50 mg	SDL
Prochlorperazine Maleate	Tablet	5 mg	SDL
Prochlorperazine Mesilate	Injection	12.5 mg/mL	SDL
Progesterone	Injection	50 mg/mL	SDL
Promethazine Hydrochloride	Syrup	5 mg/5mL	SDL
Promethazine Hydrochloride	Injection	25 mg/mL	SDL
Promethazine Hydrochloride	Syrup	5 mg/5 mL	SDL
Promethazine Theoclate	Tablet	25 mg	SDL
Propantheline Bromide	Tablet	15 mg	SDL
Propafenone Hydrochloride	Tablet	150 mg	SDL
Proparacaine Hydrochloride	Eye drops	0.5%	SDL
Propofol	Injection	10 mg/mL	SDL
Propranolol Hydrochloride	Injection	1 mg/mL	SDL
Propranolol Hydrochloride	Tablet	10 mg, 40 mg, 80 mg	SDL
Propylene Glycol	Solution	40%	SDL
Propylthiouracil	Tablet	50 mg	SDL
Protamine Sulfate	Injection	1% (10 mg/mL)	SDL
Pyrazinamide	Tablet	500 mg	SDL
Pyridostigmine Bromide	Tablet	10 mg, 60 mg	SDL
Pyridoxine Hydrochloride	Tablet	10 mg, 50 mg	SDL
Pyrimethamine	Tablet	25 mg	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Quetiapine	Tablet	25 mg, 100 mg, 200 mg	SDL
Quinine Sulfate	Tablet	300 mg	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Rabies Virus Vaccine (Inactivated)	Injection	Minimum 2.5 international units	SDL
Ranibizumab (Lucentis)	Prefilled syringe	1.65mg/0.165 mL	SDL
Ranibizumab (Lucentis)	Injection	2.3 mg/0.23 mL	SDL
Ranitidine	Injection	50 mg/2 mL	SDL
Ranitidine	Tablet	150 mg	SDL
Raltegravir	Tablet	400 mg, 600 mg	MAF	In combination with other antiretroviral agents for the treatment of HIV-1 infection
Recombinant Factor VIII (Advate)	Injection	250 international units, 500 international units, 1000 international units, 1500 international units	SDL
Recombinant Factor VIII (Xyntha)	Injection	250 international units, 500 international units, 1000 international units, 2000 international units	SDL
Recombinant factor IX (BeneFIX)	Injection	250 international units, 500 international units, 1000 international units, 2000 international units	SDL
Regorafenib	Tablet	40 mg	MAF	1) Treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumours (GISTs) who have been previously treated with imatinib mesylate. 2) Treatment of advanced unresectable hepatocellular carcinoma in patients with disease progression after 1 or more prior lines of systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system. 3) Treatment of metastatic colorectal cancer that has been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and if RAS wild-type, an anti-EGFR therapy.
Ribavirin	Capsule	200 mg	MAF	Treatment of chronic hepatitis C infection (all genotypes)
Ribavirin	Tablet	200 mg	MAF	Treatment of chronic hepatitis C infection (all genotypes)
Ribociclib	Tablet	200 mg	MAF	1) Ribociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for HR positive, HER2 negative, advanced or metastatic breast cancer. Pre/perimenopausal women treated with this combination could also receive a luteinizing hormone-releasing hormone agonist according to local clinical practice 2) Ribociclib in combination with fulvestrant for HR positive, HER2 negative, advanced or metastatic breast cancer in patients who have received prior endocrine therapy. Pre/perimenopausal women treated with this combination could also receive a luteinizing hormone-releasing hormone agonist according to local clinical practice
Rifampicin	Capsule	150 mg, 300 mg	SDL
Rifampicin	Suspension	100 mg/5 mL	SDL
Rifaximin	Tablet	550 mg	SDL
Rilpivirine	Tablet	25 mg	SDL
Risedronate Sodium	Tablet	35 mg	SDL
Risperidone	Oral solution	1 mg/mL	SDL
Risperidone	Tablet	0.5 mg, 1 mg, 2 mg	SDL
Ritonavir	Tablet	100 mg	SDL
Rituximab biosimilar (Truxima)	Concentrate for solution for infusion	100 mg/10 mL, 500 mg/50 mL	SDL
Rivaroxaban	Tablet	15 mg, 20 mg	MAF	1) Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF)* and CHA₂DS₂-VASc score of 1 or more for men, and 2 or more for women *This excludes patients with rheumatic mitral stenosis or prosthetic heart valves 2) Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE in adults. MAF assistance does not apply to patients with isolated distal DVT
Rivastigmine	Transdermal patch	4.6 mg/24 hr, 9.5 mg/24 hr, 13.3 mg/24 hr	MAF	1) Rivastigmine patch formulation (4.6 mg/24 hr and 9.5 mg/24 hr) for the treatment of moderately severe dementia associated with Parkinson's disease in patients who have behavioural symptoms 2) Rivastigmine patch formulation (4.6 mg/24 hr, 9.5 mg/24 hr and 13.3 mg/24 hr) for the treatment of moderately severe dementia associated with Alzheimer's disease in patients who have behavioural symptoms
Ropinirole	Tablet	0.25 mg, 1 mg, 2 mg	SDL
Rosuvastatin	Tablet	5 mg, 10 mg, 20 mg	SDL
Ruxolitinib	Tablet	5 mg, 15 mg, 20 mg	MAF	Treatment of patients with: a) intermediate-1 risk myelofibrosis with severe disease-related symptoms or splenomegaly that are resistant, refractory or intolerant to available therapy; or b) intermediate-2 or high-risk myelofibrosis with disease-related splenomegaly or symptoms.

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Sacubitril & valsartan	Tablet	Sacubitril 24 mg + Valsartan 26 mg tablet, Sacubitril 49 mg + Valsartan 51 mg tablet, Sacubitril 97mg + Valsartan 103 mg tablet	MAF	To reduce the risk of cardiovascular death and hospitalisation for heart failure (HF) in patients: • with chronic HF classified by NYHA Class II-IV symptoms; and • with left ventricular ejection fraction of 40% or less; and • who are receiving concomitant optimal standard chronic heart failure treatment, which includes a beta-blocker, unless contraindicated or not tolerated; and • who remain symptomatic despite already receiving a stable dose of an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB), unless such treatment is contraindicated or cannot be tolerated.
Salbutamol	Inhalation aerosol	100 mcg/dose	SDL
Salbutamol	Nebulisation solution	0.5%	SDL
Salbutamol	Concentrate for infusion	5 mg/5 mL	SDL
Salbutamol	Oral liquid	2 mg/5 mL	SDL
Salbutamol	Tablet	2 mg	SDL
Salicylic Acid	Cream	2%, 20%	SDL
Salicylic Acid	Ointment	1%, 2%, 5%, 10%, 20%, 40%	SDL
Salicylic Acid	Topical solution	10%	SDL
Salicylic Acid & Lactic Acid	Topical solution	Salicylic Acid 16.7% + Lactic Acid 16.7% Collodion	SDL
Sea Snake Venom Antiserum	Concentrate for infusion	1,000 units/dose	SDL
Secukinumab (Cosentyx)	Injection, prefilled pen	150 mg/mL	MAF	Additional clinical criteria applies 1) Treatment of adult patients with ankylosing spondylitis 2) Treatment of adult patients with psoriatic arthritis 3) Treatment of adult patients with chronic plaque psoriasis 4) Treatment of children and adolescents aged 6 years and above with chronic plaque psoriasis 5) Treatment of adult patients with non-radiographic axial spondyloarthritis
Secukinumab (Cosentyx)	Injection, prefilled pen	300 mg/2 mL	MAF	Additional clinical criteria applies 1) Treatment of adult patients with ankylosing spondylitis 2) Treatment of adult patients with psoriatic arthritis 3) Treatment of adult patients with chronic plaque psoriasis 4) Treatment of children and adolescents aged 6 years and above with chronic plaque psoriasis
Secukinumab (Cosentyx)	Prefilled syringe	75 mg/0.5 mL	MAF	Additional clinical criteria applies Treatment of children and adolescents aged 6 years and above with chronic plaque psoriasis
Selenium Sulfide	Topical suspension	2.5%	SDL
Sennosides	Tablet	7.5 mg	SDL
Sertraline	Tablet	50 mg	SDL
Sevelamer Carbonate	Tablet	800 mg	MAF	Treatment of hyperphosphataemia in patients with chronic kidney disease who have persistent hyperphosphataemia despite optimising treatment with calcium-based phosphate binders, or who are unable to tolerate calcium-based phosphate binders due to hypercalcaemia.
Silicone Cream	Cream	Dimethicone 10%, Chlorocresol 0.1%	SDL
Silver sulphadiazine & chlorhexidine digluconate	Cream	Silver sulphadiazine 1%, Chlorhexidine digluconate 0.2%	SDL
Simeticone	Oral suspension	100 mg/mL	SDL
Simvastatin	Tablet	10 mg, 20 mg	SDL
Siponimod	Tablet	0.25 mg, 2 mg	MAF	Treatment of adults with secondary progressive multiple sclerosis with active disease evidenced by relapses or imaging features of inflammatory activity.
Sirolimus	Tablet	0.5 mg, 1 mg, 2 mg	MAF	For kidney transplant immunosuppression in patients with: 1) Evidence of CNI-induced nephrotoxicity on allograft biopsy OR 2) Elevated serum creatinine levels precluding the achievement of optimal therapeutic blood levels of CNI OR 3) History of CNI drug hypersensitivity
Sirolimus	Oral solution	1 mg/mL	MAF	For kidney transplant immunosuppression in patients with: 1) Evidence of CNI-induced nephrotoxicity on allograft biopsy OR 2) Elevated serum creatinine levels precluding the achievement of optimal therapeutic blood levels of CNI OR 3) History of CNI drug hypersensitivity
Sitagliptin	Tablet	25 mg, 50 mg, 100 mg	SDL
Sodium Alginate, Sodium Bicarbonate & Calcium Carbonate	Oral suspension	Sodium Alginate 500 mg/10 mL + Sodium Bicarbonate 267 mg/10 mL + Calcium Carbonate 160 mg/10 mL	SDL
Sodium Benzoate	Injection	2 g/10 mL	SDL
Sodium Benzoate	Powder	5 g, 1 kg	SDL
Sodium Benzoate	Tablet	500 mg	SDL
Sodium Bicarbonate	Infusion	4.2%, 8.4%	SDL
Sodium Bicarbonate	Injection	4.2%, 8.4%	SDL
Sodium Bicarbonate	Capsule	500 mg	SDL
Sodium Bicarbonate	Powder	Minimum 99%	SDL
Sodium Bicarbonate & Sodium Chloride	Powder	9 parts Sodium Bicarbonate + 1 part Sodium Chloride	SDL
Sodium Calcium Edetate	Injection	500 mg/10 mL	SDL
Sodium Chloride	Infusion	0.45%, 0.9%, 3%, 20%	SDL
Sodium Chloride	Irrigation solution	0.9%	SDL
Sodium Chloride	Injection	0.45%, 0.9%, 3%, 20%	SDL
Sodium Chloride	Eye drops	0.9%, 5%	SDL
Sodium Chloride	Eye ointment	5%	SDL
Sodium Chloride & Dextrose	Sustained-release tablet	Sodium Chloride 500 mg + Dextrose 200 mg	SDL
Sodium Chloride, Calcium Chloride Dihydrate & Potassium Chloride	Infusion	Sodium Chloride 8.6 g/L + Calcium Chloride Dihydrate 0.33 g/L + Potassium Chloride 0.3 g/L	SDL
Sodium Nitrite	Injection	3%	SDL
Sodium Nitroprusside	Injection	50 mg/2 ml	SDL
Sodium Polystyrene Sulfonate	Oral suspension	15 g/60 mL	SDL
Sodium Polystyrene Sulfonate	Powder for oral suspension	99 - 100%	SDL
Sodium Tetradecyl Sulfate	Injection	1%, 3%	SDL
Sodium Thiosulfate	Injection	25%	SDL
Sodium Valproate	Controlled-release tablet	200 mg, 300 mg, 500 mg	SDL
Sodium Valproate	Enteric-coated tablet	200 mg	SDL
Sodium Valproate	Injection	400 mg	SDL
Sodium Valproate	Syrup	200 mg/5 mL	SDL
Sofosbuvir & Velpatasvir	Tablet	Sofosbuvir 400 mg + Velpatasvir 100 mg	MAF	Treatment of chronic hepatitis C infection (all genotypes) in treatment-naïve, or pegylated interferon plus ribavirin (PR)-experienced or NS3/4A protease inhibitor (boceprevir, simeprevir, telaprevir)-experienced adults. Sofosbuvir/velpatasvir should be used in line with the recommended treatment regimen and duration: • 12 weeks’ treatment of sofosbuvir/velpatasvir for patients with hepatitis C virus (all genotypes) without cirrhosis or with compensated cirrhosis (Child-Pugh A). For patients with genotype 3, the addition of ribavirin may be considered in patients who are treatment-experienced or have compensated cirrhosis (Child-Pugh A). • 12 weeks’ treatment of sofosbuvir/velpatasvir in combination with ribavirin for patients with hepatitis C virus (all genotypes) with decompensated cirrhosis (Child-Pugh B or C).
Solifenacin Succinate	Tablet	5 mg	SDL
Somatostatin (as Acetate)	Infusion	3 mg	SDL
Somatropin (SciTropin A)	Solution for injection	5 mg/1.5 mL, 10 mg/1.5 mL	SDL
Somatropin (Norditropin)	Prefilled pen	5 mg/1.5 mL, 10 mg/1.5 mL	MAF	1) Treatment of children with short stature due to conditions associated with growth failure *Somatropin is not recommended for the treatment of idiopathic short stature 2) Replacement therapy in adults with growth hormone deficiency associated with benign or malignant hypothalamic or pituitary neoplasms.
Somatropin (Zomacton, Genotropin, Saizen)	Injection	4 mg, 5.3 mg/mL, 5.83 mg/mL	MAF	1) Treatment of children with short stature due to conditions associated with growth failure *Somatropin is not recommended for the treatment of idiopathic short stature 2) Replacement therapy in adults with growth hormone deficiency associated with benign or malignant hypothalamic or pituitary neoplasms.
Somatropin (Saizen)	Injection	8 mg/mL	MAF	Replacement therapy in adults with growth hormone deficiency associated with benign or malignant hypothalamic or pituitary neoplasms.
Sorafenib	Tablet	200 mg	SDL
Sotalol hydrochloride	Tablet	80 mg	SDL
Spironolactone	Tablet	25 mg	SDL
Stiripentol	Capsule	250 mg, 500 mg	MAF	Treatment of status epilepticus in Dravet syndrome
Stiripentol	Oral suspension	250 mg, 500 mg	MAF	Treatment of status epilepticus in Dravet syndrome
Streptokinase	Infusion	1.5 million international units	SDL
Streptomycin	Injection	1 g	SDL
Sulfamethoxazole & Trimethoprim	Concentrate for infusion	Sulfamethoxazole 80 mg/mL + Trimethoprim 16 mg/mL	SDL
Sulfamethoxazole & Trimethoprim	Suspension	Trimethoprim 40 mg/5 mL + Sulphamethoxazole 200 mg/5 mL	SDL
Sulfamethoxazole & Trimethoprim	Tablet	Trimethoprim 20 mg + Sulphamethoxazole 100 mg, Trimethoprim 80 mg + Sulphamethoxazole 400 mg	SDL
Sulfasalazine	Enteric-coated tablet	500 mg	SDL
Sulphur & Salicylic Acid	Cream	Sulphur 4% + Salicylic Acid 2%	SDL
Sulphur, Resorcinol & Calamine	Lotion	Sulphur 4% + Resorcinol 2% + Calamine 10%	SDL
Sulphur, Zinc Oxide, Resorcinol & Calamine	Cream	Sulphur 4% + Zinc Oxide 8% + Resorcinol 2% + Calamine 8%	SDL
Sulpiride	Tablet	200 mg	SDL
Sumatriptan	Tablet	50 mg	SDL
Sunitinib	Capsule	12.5 mg	SDL
Suxamethonium Chloride	Injection	50 mg/mL	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Tacrolimus	Prolonged-release capsule	0.5 mg, 1 mg, 5 mg	SDL
Tacrolimus (Prograf)	Capsule	0.5 mg, 1 mg, 5 mg	SDL
Tacrolimus	Concentrate for infusion	5 mg/mL	SDL
Tamoxifen	Tablet	10 mg, 20 mg	SDL
Telmisartan	Tablet	40 mg, 80 mg	SDL
Temozolomide	Capsule	20 mg, 100 mg	SDL
Tenofovir Disoproxil Fumarate	Tablet	300 mg	SDL
Tepotinib	Tablet	225 mg	MAF	Treatment of metastatic non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition factor gene exon 14 skipping (METex14sk) alterations
Terazosin	Tablet	2 mg, 5 mg	SDL
Terlipressin acetate	Solution for injection	1 mg/8.5 mL	SDL
Testosterone Cipionate	Injection	100 mg/mL	SDL
Tetanus Immunoglobulin (Human)	Injection	250 units/dose	SDL
Tetanus Toxoid Vaccine	Injection	Minimum 40 international units/0.5 mL	SDL
Tetracycline Hydrochloride	Ointment	3%	SDL
Tetracycline Hydrochloride	Capsule	250 mg	SDL
Thalidomide	Capsule	50 mg	SDL
Theophylline	Sustained-release tablet	125 mg, 200 mg, 250 mg, 300 mg	SDL
Theophylline	Syrup	80 mg/15 mL	SDL
Thiamine Hydrochloride	Injection	100 mg/2 mL, 100 mg/mL	SDL
Thiamine Hydrochloride	Tablet	10 mg	SDL
Thiopental Sodium	Injection	0.5 g, 1 g	SDL
Thrombin	Topical solution	5,000 international units/5 mL	SDL
Ticagrelor	Tablet	90 mg	MAF	Prevention of thrombotic events (cardiovascular death, myocardial infarction and stroke) in adults with acute coronary syndromes, that is, people: • with ST-segment-elevation myocardial infarction (STEMI); or • with non-ST-segment-elevation myocardial infarction (NSTEMI); or • with unstable angina requiring hospitalisation - defined as ST or T wave changes on electrocardiogram suggestive of ischaemia plus one of the following characteristics: - age 60 years and older; - previous myocardial infarction; - previous coronary artery bypass grafting (CABG); - coronary artery disease with stenosis of 50% or more in at least two vessels; - previous ischaemic stroke; - previous transient ischaemic attack; - carotid stenosis of at least 50%; - cerebral revascularisation; - diabetes mellitus; - peripheral arterial disease; or - chronic renal dysfunction, defined as a creatinine clearance of less than 60 ml per minute per 1.73m² of body surface area. Ticagrelor should be used in combination with low-dose aspirin for up to 12 months.
Ticlopidine Hydrochloride	Tablet	250 mg	SDL
Timolol Maleate	Eye drops	0.25%, 0.5%	SDL
Tioguanine	Tablet	40 mg	SDL
Tofacitinib	Tablet	5 mg	MAF	Additional clinical criteria applies 1) Treatment of adults with rheumatoid arthritis. 2) Treatment of adults with moderately to severely active ulcerative colitis who have failed conventional therapy and/or anti-TNFα biologics.
Tolbutamide	Tablet	500 mg	SDL
Tolterodine Tartrate	Extended-release capsule	4 mg	SDL
Tolterodine Tartrate	Tablet	1 mg, 2 mg	SDL
Topiramate	Tablet	25 mg, 50 mg, 100 mg	SDL
Tramadol Hydrochloride	Capsule	50 mg	SDL
Tramadol Hydrochloride	Tablet	50 mg	SDL
Trametinib	Tablet	0.5 mg, 2 mg	MAF	1) To use with dabrafenib for treating locally advanced or metastatic anaplastic thyroid cancer in patients with a BRAF V600 mutation and with no satisfactory locoregional treatment options. 2) To use with dabrafenib for the treatment of advanced unresectable or metastatic malignant melanoma in patients with a BRAF V600 mutation. Patients must not have received prior treatment with a BRAF/MEK inhibitor for unresectable or metastatic melanoma. 3) To use with dabrafenib for the treatment of advanced non-small-cell lung cancer (NSCLC) in patients with a BRAF V600 mutation.
Tranexamic Acid	Injection	100 mg/mL	SDL
Tranexamic Acid	Tablet	500 mg	SDL
Trastuzumab Biosimilar (Herzuma)	Injection	440 mg	SDL
Trastuzumab Biosimilar (Ogivri)	Injection	440 mg	SDL
Tretinoin	Capsule	10 mg	SDL
Triamcinolone Acetonide	Injection	10 mg/mL	SDL
Triamcinolone Acetonide	Nasal spray	55 mcg/dose	SDL
Triamterene & Hydrochlorothiazide	Tablet	Triamterene 50 mg + Hydrochlorothiazide 25 mg	SDL
Trifluoperazine	Tablet	1 mg, 5 mg	SDL
Trimethoprim	Oral suspension	50 mg/5 mL	SDL
Trimethoprim	Tablet	100 mg	SDL
Tropicamide	Eye drops	0.5%, 1%	SDL
Tropicamide	Single-use eye drops	1%	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class
Umeclidinium	Inhalation powder	62.5 mcg/dose (30 doses/ inhaler)	SDL
Umeclidinium & Vilanterol	Inhalation powder	Umeclidinium 62.5 mcg/dose + Vilanterol 25 mcg/dose (30 doses/ inhaler)	SDL
Urea	Cream	5%, 10%	SDL
Ursodeoxycholic Acid	Capsule	250 mg	SDL
Ursodeoxycholic Acid	Suspension	50 mg/mL	SDL
Ursodeoxycholic Acid	Tablet	500 mg	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Valganciclovir	Tablet	450 mg	SDL
Valsartan	Tablet	80 mg, 160 mg	SDL
Vancomycin	Infusion	500 mg	SDL
Vasopressin	Injection	20 pressor units/mL	SDL
Vedolizumab (Entyvio)	Infusion	300 mg	MAF	Additional clinical criteria applies Treatment of adults with moderately to severely active Crohn’s disease who have failed both conventional therapy and anti-TNFα biologics.
Venetoclax	Tablet	10 mg, 50 mg, 100 mg	MAF	1) Monotherapy for patients with chronic lymphocytic leukaemia (CLL) who are unsuitable for fludarabine-based therapy, following combination treatment with obinutuzumab. (Maximum treatment duration of obinutuzumab is 6 cycles and venetoclax is 12 months). 2) Venetoclax in combination with rituximab biosimilar (subsidised brand) for patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. Maximum treatment duration of rituximab is 6 cycles and venetoclax is 24 months. 3) Venetoclax in combination with obinutuzumab for patients with previously untreated chronic lymphocytic leukaemia (CLL) who are unsuitable for fludarabine-based therapy. Maximum treatment duration of obinutuzumab is 6 cycles and venetoclax is 12 months.
Venlafaxine	Extended-release capsule	75 mg, 150 mg	SDL
Venlafaxine	Extended-release tablet	75 mg, 150 mg	SDL
Verapamil Hydrochloride	Injection	2.5 mg/mL	SDL
Verapamil Hydrochloride	Tablet	40 mg	SDL
Vinblastine Sulfate	Injection	10 mg	SDL
Vincristine Sulfate	Injection	1 mg	SDL
Vinorelbine	Injection	50 mg/5 mL	SDL
Vitamin A	Capsule	10,000 units	SDL
Vitamin B Complex	Injection	Thiamine Hydrochloride 10 mg/2 mL + Sodium Riboflavin Phosphate 4 mg/2 mL + Nicotinic Acid 40 mg/2 mL + Panthenol 6 mg/2 mL + Biotin 5 mg/2 mL + Pyridoxine Hydrochloride 4 mg/2 mL + Cyanocobalamin 8 mcg/2 mL	SDL
Vitamin B Complex	Tablet	Thiamine 3 mg + Riboflavine 1.5 mg + Nicotinamide 10 mg + Pyridoxine 0.5 mg	SDL
Voriconazole	Infusion	200 mg	SDL
Voriconazole	Oral suspension	40 mg/mL	MAF	1) Treatment of invasive aspergillosis 2) Treatment of candidaemia in non-neutropenic patients 3) Treatment of fluconazole-resistant candidiasis 4) Treatment of serious infections from Scedosporium and Fusarium species
Voriconazole	Tablet	50 mg, 200 mg	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Warfarin Sodium	Tablet	1 mg, 3 mg, 5 mg	SDL
White Soft Paraffin	Ointment	-	SDL

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)

Active Ingredient(s)	Dosage Form	Strength(s)	Subsidy Class	Clinical Indication (where applicable)
Zanubrutinib	Capsule	80 mg	MAF	1) Treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. 2) Monotherapy for patients with Waldenstrom's macroglobulinemia (WM) who have received at least one prior therapy. 3) Monotherapy for previously untreated Waldenstrom's macroglobulinemia (WM) in patients who are unsuitable for chemo-immunotherapy. 4) Monotherapy for relapsed or refractory marginal zone lymphoma (MZL) in patients who have received at least one prior anti-CD20-based regimen. 5) Monotherapy for chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients who have received at least one prior therapy. 6) Monotherapy for previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients who are unsuitable for fludarabine-based therapy.
Zidovudine	Capsule	100 mg	SDL
Zoledronic Acid	Infusion	5 mg/100 mL	MAF	1) For patients with osteoporosis (T score ≤ -2.5) and who are unable to tolerate or follow the administration instructions for oral bisphosphonates 2) For patients with FRAX of ≥ 20 for major osteoporotic fractures and ≥ 3 for hip fractures and who are unable to tolerate or follow the administration instructions for oral bisphosphonates
Zoledronic Acid	Infusion	4 mg	SDL
Zuclopenthixol Acetate	Injection	50 mg/mL	SDL
Zuclopenthixol Decanoate	Injection	200 mg/mL	SDL

List of Subsidised Drugs

List of Drugs* (as of 1 March 2024)

Related Content